Organon & Co. (OGN) 10-K 21 Mar 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 14, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-40235
Entity Registrant Name	Organon & Co.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4838035
Entity Address, Address Line One	30 Hudson Street, Floor 33
Entity Address, City or Town	Jersey City
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07302
City Area Code	(551)
Local Phone Number	430-6900
Title of 12(b) Security	Common Stock ($0.01 par value)
Trading Symbol	OGN
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 7,670
Entity Common Stock, Shares Outstanding		253,637,179
Documents Incorporated by Reference	The information required by Part III will be incorporated by reference from the Registrant’s definitive proxy statement for its 2022 Annual Meeting of Stockholders (the “2022 Proxy Statement”), which will be filed pursuant to Regulation 14A with the United States Securities and Exchange Commission (“SEC”) within 120 days after the end of the fiscal year to which this report relates.
Entity Central Index Key	0001821825
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Auditor [Abstract]
Auditor Location	Florham Park, New Jersey
Auditor Name	PricewaterhouseCoopers LLP
Auditor Firm ID	238

Consolidated Statement of Incom

Consolidated Statement of Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues	$ 6,304	$ 6,532	$ 7,777
Costs, Expenses and Other
Cost of sales	2,382	2,119	2,274
Selling, general and administrative	1,668	1,356	1,443
Research and development	443	210	220
Restructuring costs	3	60	78
Other (income) expense, net	279	35	66
Costs, Expenses And Other	4,775	3,780	4,081
Income From Continuing Operations Before Income Taxes	1,529	2,752	3,696
Taxes on Income	178	496	390
Net Income From Continuing Operations	1,351	2,256	3,306
Loss From Discontinued Operations - Net of Tax	0	(96)	(88)
Net Income	$ 1,351	$ 2,160	$ 3,218
Earnings (Loss) per Share Attributable to Organon & Co. Stockholders - Basic:
Continuing operations (in dollars per share)	$ 5.33	$ 8.90	$ 13.04
Discontinued operations (in dollars per share)	0	(0.38)	(0.35)
Net Earnings per Share Attributable to Organon & Co. Stockholders - Basic (in dollars per share)	5.33	8.52	12.69
Earnings (Loss) per Share Attributable to Organon & Co. Stockholders - Diluted:
Continuing operations (in dollars per share)	5.31	8.90	13.04
Discontinued operations (in dollars per share)	0	(0.38)	(0.35)
Net Earnings per Share Attributable to Organon & Co. Stockholders - Diluted (in dollars per share)	$ 5.31	$ 8.52	$ 12.69
Weighted Average Shares Outstanding:
Basic (in shares)	253,537,941	253,516,000	253,516,000
Diluted (in shares)	254,192,700	253,516,000	253,516,000

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net Income	$ 1,351	$ 2,160	$ 3,218
Other Comprehensive Income (Loss), Net of Taxes:
Benefit plan net gain (loss) and prior service credit, net of amortization	8	(143)	(60)
Cumulative translation adjustment	90	(30)	54
Other comprehensive income (loss)	98	(173)	(6)
Comprehensive Income	$ 1,449	$ 1,987	$ 3,212

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 737	$ 12
Accounts receivable (net of allowance for doubtful accounts of $7 in 2021 and $18 in 2020)	1,382	1,038
Inventories (excludes inventories of $76 in 2021 and $127 in 2020 classified in Other Assets)	915	913
Other current assets	726	930
Current assets of discontinued operations	0	674
Total current assets	3,760	3,567
Property, plant and equipment, net	973	984
Goodwill	4,603	4,603
Other intangibles, net	651	503
Other assets	694	361
Noncurrent assets of discontinued operations	0	91
Assets	10,681	10,109
Current Liabilities
Current portion of long-term debt	9	0
Trade accounts payable	1,382	259
Accrued and other current liabilities	1,021	659
Due to related party	0	1,339
Income taxes payable	185	288
Current liabilities of discontinued operations	0	128
Total current liabilities	2,597	2,673
Long-term debt	9,125	0
Deferred Income Taxes	4	128
Other noncurrent liabilities	463	1,739
Noncurrent liabilities of discontinued operations	0	83
Commitments and Contingencies
Organon & Co. Equity
Common Stock, $0.01 par value Authorized - 500,000,000 Issued and outstanding - 253,550,029	3	0
Additional paid-in capital	0	0
Accumulated deficit	(998)	0
Net investment from Merck & Co., Inc.	0	6,108
Accumulated other comprehensive loss	(513)	(622)
Total (Deficit) Equity	(1,508)	5,486
Liabilities and Equity	$ 10,681	$ 10,109

Condensed Combined Balance Shee

Condensed Combined Balance Sheet (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 7	$ 18
Inventories classified in Other Assets	$ 76	$ 127
Common stock, par value (in dollars per share)	$ 0.01
Common stock, shares authorized	500,000,000
Common stock, shares issued	253,550,029
Common stock, shares outstanding	253,550,029

Consolidated Statement of Equit

Consolidated Statement of Equity - USD ($) $ in Millions	Total	Merck and Co., Inc.	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Net Investment from Merck & Co., Inc.Merck and Co., Inc.	Accumulated Other Comprehensive (Loss) Income
Beginning balance at Dec. 31, 2018	$ 6,348		$ 0	$ 0	$ 0	$ 7,256	$ (908)
Beginning balance, shares at Dec. 31, 2018			0
Stockholders' Equity [Roll Forward]
Net income attributable to Organon & Co.	3,218					3,218
Other comprehensive loss, net of taxes	(6)						(6)
Net transfers to Merck & Co., Inc.	(2,525)	$ (2,525)				(2,525)
Ending balance at Dec. 31, 2019	7,035		$ 0	0	0	7,949	(914)
Ending balance, shares at Dec. 31, 2019			0
Stockholders' Equity [Roll Forward]
Net income attributable to Organon & Co.	2,160					2,160
Other comprehensive loss, net of taxes	(173)						(173)
Net transfers to Merck & Co., Inc.	(3,536)	(4,001)				(4,001)	(465)
Ending balance at Dec. 31, 2020	5,486		$ 0	0	0	6,108	(622)
Ending balance, shares at Dec. 31, 2020			0
Stockholders' Equity [Roll Forward]
Net income attributable to Organon & Co.	1,351				621	730
Other comprehensive loss, net of taxes	98						98
Net transfers to Merck & Co., Inc.		$ 588
Net transfers from Merck & Co., Inc., including Separation Adjustments	664				65	588	11
Net consideration paid to Merck & Co. Inc. in connection with Separation	(9,000)					(9,000)
Cash dividends declared on common stock	(145)				(145)
Stock-based compensation plans and other (in shares)			34,029
Stock-based compensation plans	38				38
Issuance of common stock in connection with the Separation and reclassification of Net investment from Merck & Co., inc. (in shares)			253,516,000
Issuance of Common Stock in connection with the Separation and reclassification of Net investment from Merck & Co., inc.	0		$ 3		(1,577)	1,574
Ending balance at Dec. 31, 2021	$ (1,508)		$ 3	$ 0	$ (998)	$ 0	$ (513)
Ending balance, shares at Dec. 31, 2021			253,550,029

Consolidated Statement of Equ_2

Consolidated Statement of Equity (Parentheticals) - $ / shares	Dec. 16, 2021	Sep. 13, 2021	Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollar per share)	$ 0.28	$ 0.28	$ 0.56

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash Flows from Operating Activities
Net income from continuing operations	$ 1,351	$ 2,256	$ 3,306
Adjustments to reconcile net income from continuing operations to net cash flows provided by operating activities:
Depreciation	92	56	49
Amortization	103	86	284
Impairment of assets	7	0	0
Acquired in-process research & development	104	0	0
Deferred income taxes	(288)	(32)	12
Stock-based compensation	59	40	41
Unrealized foreign exchange loss (gain)	18	(5)	0
Other	12	0	0
Net changes in assets and liabilities
Accounts receivable	(277)	13	200
Inventories	(138)	34	(91)
Other current assets	353	80	(105)
Trade accounts payable	663	37	(35)
Accrued and other current liabilities	329	12	(86)
Due from/due to related party	(164)	(155)	0
Income taxes payable	(119)	(118)	(590)
Other	55	(20)	35
Net Cash Flows Provided by Operating Activities from Continuing Operations	2,160	2,284	3,020
Cash Flows from Investing Activities
Capital expenditures	(192)	(255)	(92)
Proceeds from sale of property, plant and equipment	7	5	4
Acquired in-process research & development	(104)	0	0
Purchase of intangible asset - Alydia Health, net of cash acquired	(192)	0	0
Net Cash Flows Used in Investing Activities from Continuing Operations	(481)	(250)	(88)
Cash Flows from Financing Activities
Proceeds from issuance of long-term debt	9,470	0	0
Repayments of debt	(112)	0	0
Payment of long-term debt issuance costs	(118)	0	0
Proceeds from short-term borrowings from Merck & Co, Inc.	0	1,512	0
Repayments of short-term borrowings from Merck & Co., Inc.	(1,512)	0	0
Net consideration paid to Merck & Co., Inc., in connection with the Separation	(9,000)	0	0
Dividend payments	(145)	0	0
Net transfers from (to) Merck & Co., Inc.	440	(3,534)	(2,932)
Net Cash Flows Used in Financing Activities from Continuing Operations	(977)	(2,022)	(2,932)
Discontinued Operations
Net Cash Provided by (Used in) Operating Activities	298	(97)	(253)
Net Cash Used in Investing Activities	0	(8)	(14)
Net Cash (Used in) Provided by Financing Activities	(356)	(153)	311
Net Cash Flows (Used in) Provided by Discontinued Operations	(58)	(258)	44
Effect of Exchange Rate Changes on Cash and Cash Equivalents from Continuing Operations	23	0	0
Effect of Exchange Rate Changes on Cash and Cash Equivalents from Discontinued Operations	0	(3)	31
Net Increase in Cash and Cash Equivalents	667	(249)	75
Cash and Cash Equivalents, Beginning of Period	12	0	0
Cash and Cash Equivalents of Discontinued Operations, Beginning of Period	58	319	244
Total Cash and Cash Equivalents, End of Period	737	70	319
Less: Cash and Cash Equivalents of Discontinued Operations, End of Period	0	58	319
Cash and Cash Equivalents, End of Period	$ 737	$ 12	$ 0

Background and Nature of Operat

Background and Nature of Operations	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Nature of Operations	Background and Nature of Operations Organon & Co. (“Organon”) is a global health care company formed through a spinoff from Merck & Co., Inc. (“Merck”) to focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands (the "Organon Products"). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom ("UK"). Unless otherwise indicated, trademarks appearing in italics are trademarks of the Organon group of companies. On June 2, 2021, Organon and Merck & Co., Inc. ("Merck") entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly traded company (the "Separation"). In connection with the Separation, on June 2, 2021, Merck distributed (the "Distribution"), on a pro rata basis, to holders of the outstanding shares of common stock of Merck, par value $0.50 per share (the "Merck Common Stock") on May 17, 2021 (the "Record Date"), all of the outstanding shares of common stock, par value $0.01 per share, of Organon (the "Common Stock"). Each Merck shareholder was entitled to receive one-tenth of a share of the Common Stock for each share of Merck Common Stock held on the Record Date. Organon is now a standalone publicly traded company and, on June 3, 2021, regular-way trading of the Common Stock commenced on the New York Stock Exchange under the ticker symbol "OGN." The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation, including, but not limited to a tax matters agreement (the "Tax Matters Agreement" or "TMA"), an employee matters agreement (the "Employee Matters Agreement") and a transition services agreement (the "Transition Service Agreement" or "TSA") (see Note 19 for additional details). The Company’s operations include the following product portfolios: • Women’s Health : the Company has a portfolio of contraception and fertility brands, such as Nexplanon/Implanon NXT (etonogestrel implant), a long-acting reversible contraceptive, which is a class of contraceptives that are recognized as the most effective type of hormonal contraception available to patients with a lower long-term average cost. • Biosimilars: the Company’s current portfolio spans across immunology and oncology treatments. All five of the biosimilars in Organon’s portfolio have launched in certain countries globally, including two biosimilars in the United States. • Established Brands : the Company has a portfolio of established brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The historical results prior to Separation included certain Merck non-U.S. legal entities that were conveyed to Organon in connection with the Separation (collectively, the "Transferred Entities" and each, a "Transferred Entity") and included operations related to other Merck products that were retained by Merck ("Merck Retained Products"). The Merck Retained Products business of the Transferred Entities was contributed by the Company to Merck and its affiliates and any remaining assets and liabilities were transferred as of June 2, 2021. Accordingly, the historical results of operations of the Merck Retained Products have been reflected as discontinued operations in these Consolidated Financial Statements (see Note 2).

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation On June 2, 2021, the Company became a standalone publicly traded company, and its financial statements are now presented on a consolidated basis. Prior to the Separation on June 2, 2021, the Company’s historical combined financial statements were prepared on a standalone basis and were derived from Merck’s consolidated financial statements and accounting records. The financial statements for all periods presented, including the historical results of the Company prior to June 2, 2021, are now referred to as "Consolidated Financial Statements", and have been prepared pursuant to the rules and regulations for reporting on Form 10-K. Periods Prior to Separation The assets, liabilities, revenue and expenses of the Company were reflected in the Consolidated Financial Statements on a historical cost basis, as included in the consolidated financial statements of Merck, using the historical accounting policies applied by Merck. The Consolidated Financial Statements did not purport to reflect what the Company’s results of operations, comprehensive income, financial position, equity or cash flows would have been had the Company operated as a standalone public company during the periods presented. The Consolidated Financial Statements were prepared following a legal entity approach, which resulted in the inclusion of the following: • Certain assets and liabilities, results of operations and cash flows attributable to the sales of Organon Products that were contributed to Organon prior to the consummation of the Separation. • The Transferred Entities, which have historically included the results from the sales of both Organon Products and the Merck Retained Products. Each Transferred Entity’s historical operations, including its results of operations, assets and liabilities, and cash flows have been fully reflected in the Consolidated Financial Statements. • In contemplation of the Separation, the Merck Retained Products business of the Transferred Entities was distributed to Merck and its affiliates ("MRP Distribution") and, accordingly, the historical results of operations, assets and liabilities, and the cash flows of the Merck Retained Products for such Transferred Entities are reflected as discontinued operations. The Company’s businesses had historically functioned together with the other businesses controlled by Merck. Accordingly, the Company relied on Merck’s corporate and other support functions for its business. Therefore, for the period prior to the Separation, certain corporate and shared costs were allocated to the Company based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method, including: (i) expenses related to Merck support functions, including expenses for facilities, executive oversight, treasury, finance, legal, human resources, shared services, compliance, procurement, information technology and other corporate functions. (ii) certain manufacturing and supply costs incurred by Merck’s manufacturing division, including facility management, distribution, logistics, planning and global quality. (iii) certain costs incurred by Merck’s human health division in relation to selling and marketing activities, and related administrative support functions, that are not routinely allocated to therapeutic areas. (iv) certain costs incurred by Merck’s research laboratories for activities related to drug discovery and development, as well as medical and regulatory affairs. (v) restructuring costs (see Note 6) and stock-based compensation expenses (see Note 13); and (vi) certain compensation expenses maintained on a centralized basis such as certain employee benefit expenses. Management believes these cost allocations were a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Company during the period prior to the Separation, though the allocations may not be indicative of the actual costs that would have been incurred had the Company operated as a standalone public company. Actual costs that may have been incurred if the Company had been a standalone company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Company’s employees, and strategic decisions made in areas such as manufacturing, selling and marketing, research and development, information technology and infrastructure. Merck maintains various employee benefit plans in which the Company’s employees participated during periods prior to the Separation, and a portion of the costs associated with these plans was included in the Company’s Consolidated Financial Statements. The Consolidated Balance Sheet at December 31, 2020 only includes assets and liabilities relating to plans for which the entity being transferred was the plan sponsor. Certain pension assets and obligations were transferred by Merck into legal entities established to operate the Organon Products business (the "Organon Entities") that are the plan sponsor and, accordingly, the Consolidated Balance Sheet at December 31, 2021 includes assets and liabilities of the newly established plans of Organon. Merck utilized a centralized approach to cash management and the financing of its operations. Cash generated by the Company was routinely transferred into accounts managed by Merck’s centralized treasury function and cash disbursements for the Company’s operations prior to the Separation were funded as needed by Merck. Cash and cash equivalents of the Organon Entities and the Transferred Entities were reflected in the Company’s Consolidated Balance Sheet. Balances held by the Organon Entities and the Transferred Entities with Merck for cash transfers and loans were reflected as Due to related party prior to Separation. All other cash, cash equivalents, short-term investments and related transfers between Merck and the Company were generally held centrally through accounts controlled and maintained by Merck and were not specifically identifiable to the Company. Accordingly, such balances were accounted for through Net investment from Merck & Co., Inc . Merck’s third-party debt and related interest expense were not attributed to the Company because the Company was not the legal obligor of the debt and the borrowings were not specifically identifiable to the Company. For the Organon Entities and the Transferred Entities, transactions with Merck affiliates were included in the Consolidated Statement of Income and related balances were reflected as Due to related party or Due from related party in the continuing operations and discontinued operations of the Consolidated Balance Sheet, as applicable. Other balances between the Company and Merck were considered to be effectively settled in the Consolidated Financial Statements at the time the transactions were recorded. See Note 19 for additional details. As the separate legal entities that made up the Company’s business were not historically held by a single legal entity, Net investment from Merck & Co., Inc. was shown in lieu of stockholders’ equity in these Consolidated Financial Statements. Net investment from Merck & Co., Inc. represented Merck’s interest in the recorded assets of the Company and the cumulative investment by Merck in the Company through the date of Separation, inclusive of operating results. Income tax expense and tax balances in the Consolidated Financial Statements were calculated on a separate tax return basis. The Company’s operations are included in the tax returns of certain Organon Entities, Transferred Entities or the respective Merck entities of which the Company’s business was a part. As of Separation Date Certain assets and liabilities, including accounts receivables, inventories and trade payables included on the Consolidated Balance Sheet prior to the Separation, have been retained by Merck post-Separation and therefore were transferred to Merck through Net investment from Merck & Co., Inc. in the Company’s Consolidated Financial Statements. Additionally, certain amounts previously included in Due to related party or Due from related party are reflected in accounts receivable and trade accounts payable as of December 31, 2021. As part of the Separation, Net investment from Merck & Co., Inc. was reclassified to Common Stock and Accumulated Deficit . In connection with the Separation, additional pension assets and obligations were transferred to Organon through Net investment from Merck & Co., Inc. , and the Company recorded these in the Consolidated Balance Sheet. See Note 14 for details. Additionally, stock-based awards were converted in accordance with the Employee Matters Agreement. See Note 13 for details. During the second quarter of 2021, an aggregate of $9.5 billion of debt was issued in connection with the Separation. (see Note 11 for additional details). The Company distributed $9.0 billion of the $9.5 billion proceeds to Merck in accordance with the terms of the Separation. Periods Post Separation Following the Separation, certain functions continue to be provided by Merck under the Transition Services Agreement or are being performed using the Company’s own resources or third-party service providers. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for Merck or its applicable affiliate, and Merck manufactures certain products for the Company or its applicable affiliate. The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company. Property, plant and equipment reflected in the Consolidated Balance Sheet is primarily attributable to the six manufacturing facilities the Company operates and certain information technology assets. In June 2021, the Company established a balance sheet risk management and a net investment hedging program to mitigate against volatility of changes in foreign exchange rates. As a standalone entity, the Company files tax returns on its own behalf, and tax balances and effective income tax rate may differ from the amounts reported in the historical periods. As of June 2, 2021 and in connection with the Separation, the Company adjusted its deferred tax balances and computed its related tax provision to reflect operations as a standalone entity. All intercompany transactions and accounts within Organon have been eliminated. Certain amounts presented in the prior period have been reclassified to conform to the current period presentation. During 2021, the Company recorded an out-of-period adjustment of approximately $145 million to establish a prepaid tax asset with an offsetting increase to Net Investment from Merck & Co., Inc . related to the period as of December 31, 2020. The adjustment did not have any impact on the Company's Consolidated Statement of Income or Consolidated Statement of Cash Flows. The Company concluded that the adjustment was not material to the Consolidated Financial Statements for either the current period or prior periods.

Summary of Accounting Policies

Summary of Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Accounting Policies	Summary of Accounting Policies Revenue Recognition — Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. The Company acts as the principal in its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts have a single performance obligation — the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation. Revenues from sales of products, including tenders, are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. In the United States, sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, revenues are recorded net of time value of money discounts if collection of accounts receivable is expected to be in excess of one year. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The Company estimates the provision for chargebacks based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector, (Managed Care), and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history to estimate the expected provision. The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $2.0 billion in 2021, $1.8 billion in 2020, and $1.9 billion in 2019. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates in the United States included in Accounts receivable and Accrued and other current liabilities were $54 million and $275 million, respectively, at December 31, 2021 and $41 million and $302 million, respectively, at December 31, 2020. Outside of the United States, variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale. At December 31, 2021 and 2020, the accrued balances related to the provision for rebates and discounts included in other current liabilities were approximately $90 million and $115 million, respectively. The Company maintains a returns policy that allows its U.S. customers to return product within a specified period prior to and subsequent to the expiration date (generally, three The Company’s payment terms for U.S. customers are typically 36 days from receipt of invoice. Outside of the United States, payment terms are typically 30 days to 90 days, although certain markets have longer payment terms. See Note 18 for disaggregated revenue disclosures. Cash Equivalents — Cash equivalents are comprised of certain highly liquid investments with original maturities of three months or less. Inventories — Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Value Added Tax — The Company’s purchases, sales and intercompany transfers of goods are subject to value added tax (VAT) and VAT receivables are recognized for amounts that represent credits against future VAT obligations. VAT receivables included in Other current asset s were $115 million and $315 million as of December 31, 2021 and 2020, respectively. VAT payables included in Accrued and other current liabilities were $9 million and $38 million as of December 31, 2021 and 2020, respectively. The related expense is included in the Company's operating expenses. Depreciation — Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. The estimated useful lives primarily range from 25 to 40 years for buildings, and from 3 to 15 years for machinery, equipment and office furnishings. Depreciation expense was $92 million in 2021, $56 million in 2020, and $49 million in 2019. Repairs and maintenance costs are expensed as incurred as they do not extend the economic life of an asset. Advertising and Promotion Costs — Advertising and promotion costs are expensed as incurred and included in Selling, general and administrative expenses . The Company recorded advertising and promotion expenses of $236 million, $198 million, and $262 million in 2021, 2020 and 2019, respectively. Goodwill — Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is evaluated for impairment as of October 1 each year, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that fair value is less than carrying value. If the Company concludes it is more likely than not that fair value is less than carrying value, a quantitative fair value test is performed. If carrying value is greater than fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill). The Company completed the annual goodwill impairment test as of October 1, 2021 and concluded that no impairment to goodwill was necessary as the fair value of the reporting unit was significantly in excess of the carrying value. Acquired Intangibles — Acquired intangibles include products and product rights and licenses, which are initially recorded at fair value, assigned an estimated useful life, and amortized on a straight-line basis over their estimated useful lives. The Company's intangibles also include the products and product rights intangible assets attributed to Organon from Merck. The intangible assets attributable to the Company’s operations have been reflected in the consolidated financial statements based on Merck’s historical cost. Licenses include milestone payments made to collaborative partners upon or subsequent to regulatory approval. The estimated useful lives of acquired intangibles range from 5 to 15 years (see Note 10). The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows. Acquired In-Process Research and Development — IPR&D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, Organon will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&D for impairment as of October 1 each year, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results. There were no IPR&D intangible assets as of December 31, 2021 or December 31, 2020. Research and Development — Research and development costs are expensed as incurred. Research and development costs also include upfront and milestone payments related to asset acquisitions, licensing or collaborative arrangements involving clinical development programs that have not yet received regulatory approval. Foreign Currency Translation — The net assets of international operations where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in Accumulated other comprehensive loss and reflected as a separate component of equity. For those operations that operate in highly inflationary economies and for those operations where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Other (income) expense, net. Organon calculates foreign currency translation on its consolidated assets and liabilities. For periods prior to the Separation, these consolidated financial statements include Merck’s foreign currency translation for the Organon Entities. Stock-Based Compensation — Prior to the Separation, certain of the Company’s employees historically participated in Merck’s share-based compensation plans. Share-based compensation expense was either allocated to the Company based on a proportionate cost allocation method or recorded based on specific identification. Effective June 3, 2021, Organon established the 2021 Incentive Stock Plan (the "Plan"). A total of 35 million shares of Common Stock are authorized under the Plan. The plan provides for the grant of various types of awards, including restricted stock unit awards, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. Accordingly, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants. The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change (see Note 13). Pension and Other Postretirement Benefit Plans — Prior to the Separation, the defined benefit plans in which the Company participated related primarily to plans sponsored by Merck and for which other businesses of Merck also participate (Shared Plans). The Company accounted for the Shared Plans as multiemployer plans and therefore the related assets and liabilities were not reflected in the Consolidated Balance Sheet. For such periods prior to Separation, the Consolidated Statement of Income reflects a proportional allocation of net periodic benefit cost for the Shared Plans associated with the Company. For certain defined benefit plans attributable to the Organon Entities, the over funded or underfunded status of the plan was recognized as an asset or liability on the combined balance sheet. The Company's participation in the defined pension and postretirement benefit plans sponsored by Merck concluded upon the completion of the Separation on June 2, 2021. At Separation, Organon became the plan sponsor for certain non-U.S. defined benefit pension plans (see Note 14). Restructuring Costs — Costs associated with exit or disposal activities are recognized in the period in which they are incurred. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. When accruing these costs, the Company recognizes the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Contingencies and Legal Defense Costs — The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. Taxes on Income — Prior to the Separation, income tax expense and deferred tax balances were calculated on a separate tax return basis. The Company’s operations were included in the tax returns of certain Organon Entities, Transferring Entities or the respective Merck entities of which the Company’s business was a part. Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company establishes valuation allowances for its deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of Taxes on Income in the Consolidated Statement of Income. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company and Merck entered into the Tax Matters Agreement in connection with the Separation (See Note 19). Leases — The Company has operating leases primarily for real estate. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if the Company controls the use of that asset. Embedded leases are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Real estate leases for facilities have a weighted average remaining lease term of 6.0 years and include one lease with an option to extend for 1 year. The Company has made an accounting policy election not to record short-term leases (leases with an initial term of 12 months or less) on the balance sheet. Lease expense associated with short term leases was not material for all periods presented. Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since most of the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments. On a quarterly basis, an updated incremental borrowing rate is determined based on the weighted average remaining lease term of each asset class and the Company's pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. The Company includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed) (See Note 11). Use of Estimates — The presentation of these Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported. Estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, amounts recorded for contingencies, environmental liabilities, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill), investments, and taxes on income. Additionally estimates are used in acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. For periods prior to Separation, estimates were used in determining the allocation of costs and expenses from Merck, and were used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, valuation of goodwill and intangibles, amounts recorded for contingencies, environmental liabilities and other reserves, pension and share-based compensation assumptions, restructuring costs, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates. The COVID-19 pandemic continued to negatively affect the Company's results during 2021. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic at December 31, 2021 and through the date of this report. Net Investment from Merck & Co., Inc. — Net investment from Merc k & Co., Inc. represented Merck’s interest in the recorded assets of the Company and the cumulative investment by Merck in the Company through the date of Separation, inclusive of operating results and the net effect of the transactions with and allocations from Merck. See Notes 2 and 19 for additional information. Recently Adopted Accounting Standards In January 2020, the Financial Accounting Standards Board ("FASB") issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company’s Consolidated Financial Statements upon adoption. In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities, clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination, and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company’s Consolidated Financial Statements upon adoption. Recently Issued Accounting Standards Not Yet Adopted In November 2021, the FASB issued new guidance requiring disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model. The guidance increases transparency about the types of transactions, the accounting for the transactions, and the effect of the transactions to the Company’s financial statements. The guidance is effective for the annual periods beginning in 2022 and can be applied on a prospective or retrospective basis. The Company is currently evaluating the impact of adoption on its Consolidated Financial Statements. In October 2021, the FASB issued guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance is effective for the Company on January 1, 2023 and its amendments applied prospectively to business combinations occurring on or after the effective date of the guidance. Early adoption is permitted, including adoption in an interim period and subject to different transition requirements. T he Company is currently evaluating the impact of adoption on its Consolidated Financial Statements. In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its Consolidated Financial Statements.

Samsung Collaboration

Samsung Collaboration	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Samsung Collaboration	Samsung Collaboration The Company has an agreement with Samsung Bioepis Co., Ltd. ("Samsung Bioepis") to develop and commercialize multiple pre-specified biosimilar candidates, which have since launched and are part of the Company’s product portfolio. Under the agreement, Samsung Bioepis is responsible for pre-clinical and clinical development, process development and manufacturing, clinical trials and registration of product candidates, and the Company has an exclusive license for worldwide commercialization with certain geographic exceptions specified on a product-by-product basis. The Company’s access rights to each product under the agreement last for 10 years from each product’s launch date on a market-by-market basis. Gross profits are shared equally in all markets with the exception of Brazil where gross profits are shared 65% to Samsung Bioepis and 35% to the Company. Since the Company is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Generally, profit sharing adjustments are recorded either to Cost of sales (after commercialization) or Selling, general and administrative expenses (prior to commercialization). Samsung Bioepis is eligible for additional payments associated with pre-specified clinical and regulatory milestones. At December 31, 2021, potential future regulatory milestone payments of $25 million remain under the agreement. Summarized information related to this collaboration is as follows: ($ in millions) 2021 2020 2019 Sales $ 424 $ 330 $ 252 Cost of sales 248 208 152 Selling, general and administrative 83 87 91 ($ in millions) December 31, 2021 December 31, 2020 Receivables from Samsung included in Other current assets $ 15 $ 52 Payables to Samsung included in Trade accounts payable 21 13

Acquisitions and Licensing Arra

Acquisitions and Licensing Arrangements	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisitions and Licensing Arrangements	Acquisitions and Licensing Arrangements In December 2021, Organon completed its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor ("HSD17B1 inhibitor") in early development for endometriosis, being evaluated for its potential effect on endometriotic lesions. Total consideration includes a $75 million upfront payment, the assumption of approximately $10 million of Forendo debt, payments upon the achievement of certain development and regulatory milestones of up to $270 million and commercial milestones payments of up to $600 million, which together could amount to total consideration of $955 million. Contingent consideration will be paid by Organon upon achievement and the liability recorded once it is deemed probable of occurrence. The transaction was accounted for in 2021 as an asset acquisition, as substantially all of the value was concentrated in a single identifiable asset, the HSD17B1 inhibitor. During the year ended December 31, 2021, the Company recorded $79 million, which consisted of the $75 million upfront payment, the assumption of debt of $10 million, and other net assets, as Research and Development expense . The Company also incurred $5.0 million of transaction related expenses reflected in Selling, General and Administrative expenses . In July 2021, Organon and ObsEva entered into a license agreement whereby Organon licensed the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. Under the terms of the license agreement, Organon gained exclusive worldwide rights to develop and commercialize ebopiprant. ObsEva is entitled to receive tiered double-digit royalties on commercial sales, up to $90 million in development and regulatory milestone payments, and up to $385 million in sales-based payments that will be paid by Organon upon achievement of the contractual milestone and the liability recorded once it is deemed probable of occurrence. Upon execution of the agreement, Organon made a $25 million upfront payment to ObsEva, which was recorded as Research and development expense during 2021. In June 2021, Organon acquired Alydia Health ("Alydia"), a commercial-stage medical device company. Alydia’s device, the Jada system, is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Organon’s acquisition of Alydia expanded its portfolio into the medical device category and underscores its commitment to identify options for women’s unmet medical needs. Total consideration included a $219 million upfront payment. Additionally, there is a $25 million sales-based contingent milestone payment that will be paid by Organon upon achievement and the liability recorded once it is deemed probable of occurrence. The transaction was accounted for as an asset acquisition, as substantially all of the value was concentrated in a single identifiable asset. This resulted in an intangible of $247 million attributed to the Jada system device, which was recorded to Other Intangibles . This asset is subject to amortization on a straight-line basis over its expected useful life of 11 years. In addition to the intangible asset, the Company also recorded other net liabilities of $7 million, a deferred tax liability of $44 million related to the intangible asset, and compensation expenses of $23 million, which were recorded in Selling General and Administrative Expense s. Of the $23 million of compensation expense, $19 million were related to accelerated vesting of Alydia stock-based compensation awards.

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring Currently, Organon does not have an established restructuring program. Restructuring costs for 2021, 2020 and 2019 were $3 million, $60 million and $78 million, respectively, and reflect only charges allocated to Organon. The restructuring costs for 2020 were comprised of $30 million of separation costs and $30 million related to other restructuring activities. The restructuring costs for 2019 were comprised of $70 million of separation costs and $8 million related to other restructuring activities. There were no liabilities for costs associated with restructuring activities at December 31, 2021. Liabilities for costs associated with restructuring activities were $17 million at December 31, 2020 and are included primarily in Accrued and other current liabilities .

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments Prior to the Separation, Merck managed the impact of foreign exchange rate movements on its affiliates’ earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments. Merck established revenue hedging and balance sheet risk management programs that the Company participated in to protect against the volatility of future foreign currency cash flows and changes in fair value caused by volatility in exchange rates. Accordingly, the Consolidated Statement of Income includes the impact of Merck’s derivative financial instruments prior to the Separation that is deemed to be associated with the Company’s operations and has been allocated to the Company utilizing a proportional allocation method: ($ in millions) 2021 2020 2019 Allocated net (gains) loss in Sales $ 56 $ 3 $ (58) Net (gains) loss in Other (income) expense, net (1) 32 48 3 Foreign exchange (gains) loss in Other (income) expense, net (1) (28) (4) 70 (1) Includes net gains and losses and foreign exchange gains and losses allocated for the period prior to the Separation, as well as actual net gains and losses and foreign exchange gains and losses post-Separation. Foreign Currency Risk Management Periods Post Separation In June 2021, the Company established a balance sheet risk management and a net investment hedging program to mitigate against volatility of changes in foreign exchange rates. The Company uses a balance sheet risk management program to mitigate the exposure of net monetary assets of its subsidiaries that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Organon principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Swiss franc and Japanese yen. For exposures in developing country currencies, the Company enters into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net . The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year. As of December 31, 2021, the fair value of these contracts was recorded as an asset of $19 million in Other current assets and a liability of $5 million in Accrued and other current liabilities . The notional amount of forward contracts was $2.1 billion as of December 31, 2021. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. Foreign exchange risk is also managed through the use of economic hedges on foreign currency debt (see Note 11). In each quarter subsequent to the Separation, €1.75 billion in the aggregate of both the euro-denominated term loan (€750 million) and of the 2.875% euro-denominated secured notes (€1.25 billion) has been designated and is effective as an economic hedge of the net investment in euro-denominated subsidiaries. As a result, $162 million of foreign currency gains due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustments in Other Comprehensive Income for 2021. Concentrations of Credit Risk Historically, the Company’s operations formed part of Merck’s monitoring of concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which Merck conducted business. Credit exposure limits were established to limit a concentration with any single issuer or institution. The majority of the Company’s accounts receivable arise from product sales in the United States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers. The Company’s customers with the largest accounts receivable balances are Curascript Specialty Distribution, McKesson Corporation and Amerisource Bergen Corporation which, represented, in aggregate, approximately 20% of total gross account receivable at December 31, 2021. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales. Merck had established accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. In connection with the Separation, Merck conveyed these agreements to Organon. Under these agreements, Organon factored $87 million in the fourth quarter of 2021 and Merck factored $227 million of accounts receivable related to the Company in the fourth quarter of 2020, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of: ($ in millions) December 31, 2021 December 31, 2020 Finished goods $ 377 $ 351 Raw materials 95 35 Work in process 490 595 Supplies 40 60 Total (approximates current cost) $ 1,002 $ 1,041 Decrease to LIFO costs (11) (1) $ 991 $ 1,040 Recognized as: Inventories $ 915 $ 913 Other assets 76 127 Inventories valued under the LIFO method comprised $52 million and $48 million at December 31, 2021 and December 31, 2020, respectively. Amounts recognized as Other assets are comprised primarily of raw materials and work in process inventories and are not expected to be converted to finished goods that will be sold within one year. The Company has a long-term vendor supply contract conveyed as part of the Separation that includes certain annual minimum purchase commitments. During 2021, the Company recorded $24 million within Other noncurrent liabilities due to estimated unavoidable losses associated with the supply contract. The charge was recognized as a component of Cost of Sales during 2021 . As of December 31, 2021, total inventory purchase obligations are $1.5 billion and extend through 2030. Inventory purchase obligations due within the next twelve months amount to $349 million.

Property, Plant, and Equipment

Property, Plant, and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment ($ in millions) December 31, 2021 December 31, 2020 Land $ 14 $ 14 Building 667 647 Machinery, equipment and office furnishings 917 787 Construction in progress 257 356 Less: accumulated depreciation (882) (820) Property, Plant and Equipment, net $ 973 $ 984

Other Intangibles

Other Intangibles	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangibles	Other Intangibles Other intangibles as of December 31 consists of: 2021 2020 ($ in millions) Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Products and product rights $ 24,195 $ 23,654 $ 541 $ 24,159 $ 23,787 $ 372 Licenses 201 91 110 201 70 131 $ 24,396 $ 23,745 $ 651 $ 24,360 $ 23,857 $ 503 Acquired intangibles include products and products rights, and licenses, which are initially recorded at fair value, assigned an estimated useful life, and amortized on a straight-line basis over their estimated useful lives. The Company’s most significant acquired intangible asset balance included in products and product rights above related to Nexplanon/Implanon , which had a net balance of $296 million and $354 million at December 31, 2021 and 2020, respectively. During 2021, Organon acquired intangibles of $247 million related to the Jada sys tem device associated with the Alydia acquisition. The most significant amounts within licenses relate to capitalized milestone payments associated with the Samsung Bioepis collaboration (see Note 4), which had a net balance of $87 million and $113 million in the aggregate at December 31, 2021 and 2020, respectively. During 2021, due to increased competition which resulted in the loss of contract tenders in certain markets and pricing pressure, the Company recorded an impairment charge of $7 million related to a product right for a biosimilar product within Cost of sales . Aggregate amortization expense recorded within Cost of sales was $103 million in 2021, $86 million in 2020 and $284 million in 2019. The estimated aggregate amortization expense for each of the next five years is as follows: 2022, $108 million; 2023, $107 million; 2024, $101 million; 2025, $99 million; 2026, $94 million.

Long-Term Debt and Leases

Long-Term Debt and Leases	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Long-Term Debt and Leases	Long-Term Debt and Leases Long-Term Debt In April 2021, in connection with the Separation, Organon Finance 1 LLC ("Organon Finance 1"), a subsidiary of Merck, issued €1.25 billion aggregate principal amount of 2.875% senior secured notes due 2028, $2.1 billion aggregate principal amount of 4.125% senior secured notes due 2028 and $2.0 billion aggregate principal amount of 5.125% senior unsecured notes due 2031 (collectively, the “Notes”). Interest payments are due semiannually on October 30 and April 30. As part of the Separation, on June 2, 2021, Organon and a wholly-owned Dutch subsidiary of Organon, (the "Dutch Co-Issuer") assumed the obligations under the Notes as co-issuers, Organon Finance 1 was released as an obligor under the Notes, and certain subsidiaries of Organon agreed to guarantee the Notes. Each series of Notes was issued pursuant to an indenture dated April 22, 2021, between Organon and U.S. Bank National Association. Organon and the Dutch Co-Issuer assumed the obligations under the Notes pursuant to a first supplemental indenture to the relevant indenture, and the guarantors agreed to guarantee the Notes pursuant to a second supplemental indenture to the relevant indenture. On June 2, 2021, Organon entered into a credit agreement with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent (the “Senior Credit Agreement”), providing for: • a Term Loan B Facility (“Term Loan B Facility”), consisting of (i) a U.S. Dollar denominated senior secured “tranche B” term loan in the amount of $3.0 billion, and (ii) a euro denominated senior secured “tranche B” term loan in the amount of €750 million, in each case with a seven-year term that matures in 2028; and • a Revolving Credit Facility (“Revolving Credit Facility” and, together with the Term Loan B Facility, the “Senior Credit Facilities”), in an aggregate principal amount of up to $1 billion, with a five-year term that matures in 2026. Borrowings made under the Senior Credit Agreement initially bear interest, in the case of: • term loans under the Term Loan B Facility (i) denominated in U.S. Dollars, at 3.00% in excess of Adjusted LIBOR (subject to a floor of 0.50%) or 2.00% in excess of an alternate base rate ("ABR"), at our option, and (ii) denominated in euros, at 3.00% in excess of an adjusted Euro Interbank Offer Rate (“Adjusted EURIBOR”) (subject to a floor of 0.00%); and • revolving loans under the Revolving Credit Facility (i) in U.S. Dollars, at 2.00% in excess of an Adjusted LIBOR (subject to a floor of 0.00%) or 1.00% in excess of ABR, at our option, and (ii) in euros, at 2.00% in excess of an Adjusted EURIBOR. The interest rate on revolving loans under the Revolving Credit Facility is subject to a step-down based on meeting a leverage ratio target. A commitment fee applies to the unused portion of the Revolving Credit Facility, initially equal to 0.50% and subject to a step-down to 0.375% based on meeting a leverage ratio target. There were no outstanding balances under the Revolving Credit Facility as of December 31, 2021. Interest payments on the term loans are due quarterly on March, June, September and December. Principal payments on the term loans are based on 0.25% of the principal amount outstanding on the Closing Date and due on the last business day of each March, June, September and December, commencing with the last business day of September 2021. Organon used the net proceeds from the Notes offering, together with available cash on its balance sheet and borrowings under senior secured credit facilities, to distribute $9.0 billion to Merck and to pay fees and expenses related to the Separation. The Senior Credit Agreement contains customary financial covenants, including a total leverage ratio covenant, which measures the ratio of (i) consolidated total debt to (ii) consolidated earnings before interest, taxes, depreciation and amortization, and subject to other adjustments, that must meet certain defined limits which are tested on a quarterly basis beginning September 30, 2021. In addition, the Senior Credit Agreement contains covenants that limit, among other things, Organon’s ability to prepay, redeem or repurchase its subordinated and junior lien debt, incur additional debt, make acquisitions, merge with other entities, pay dividends or distributions, redeem or repurchase equity interests, and create or become subject to liens. As of December 31, 2021, the Company is in compliance with all financial covenants and no default or event of default has occurred. The following is a summary of Organon's total debt as described above: ($ in millions) December 31, 2021 Term Loan B Facility: LIBOR plus 300 bps term loan due 2028 $ 2,893 LIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million) 843 4.125% secured notes due 2028 2,100 2.875% euro-denominated secured notes due 2028 (€1.25 billion) 1,412 5.125% notes due 2031 2,000 Other borrowings 10 Other (discounts and debt issuance costs) (124) Total principal long-term debt $ 9,134 Less: Current portion of long-term debt 9 Total Long-term debt, net of current portion $ 9,125 Other borrowings represent debt assumed in connection with the Forendo acquisition. In 2021, the Company recorded approximately $117 million of debt issuance costs related to the long-term debt and $19 million of discounts on the term loans. Debt issuance costs and discounts are presented as a reduction of debt on the Consolidated Balance Sheets and are amortized as a component of interest expense over the term of the related debt using the effective interest method. The unamortized debt issuance costs related to the long-term debt and discounts on the term loans at December 31, 2021 are approximately $124 million. The estimated fair value of long-term debt (including current portion) at December 31, 2021, was $9.4 billion compared with a carrying value (which includes a reduction for amortized debt issuance costs) of $9.1 billion. Fair value was estimated using inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability and would be considered Level 2 in the fair value hierarchy. The Company made interest payments of $188 million related to its debt instruments during the year ended December 31, 2021. The average maturity of the Company's long-term debt at December 31, 2021 is approximately 7 years and the weighted-average interest rate on total borrowings for the three months ended December 31, 2021 is 3.9%. On December 23, 2021, the Company made a discretionary prepayment of $100 million on the U.S. dollar denominated term loan. The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows: ($ in millions) 2022 $ 9 2023 9 2024 9 2025 37 2026 43 Thereafter 9,151 Leases For periods prior to the Separation, lease costs were allocated to the Company based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method. Allocated operating lease cost for periods prior to Separation and actual operating lease cost was $66 million, $40 million and $45 million for 2021, 2020 and 2019, respectively. None of the Company’s lease agreements contain variable lease payments. Sublease income is immaterial and there are no sale-leaseback transactions. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. Cash paid for amounts included in the measurement of operating lease liabilities was $41 million, $5 million, and $6 million in 2021, 2020 and 2019, respectively. Operating lease assets obtained in exchange for new operating lease liabilities were $241 million , $23 million and $4 million for 2021 and 2020 , and 2019, respectively and primarily consists of real estate operating leases entered into in connection with establishing Organon as a standalone Company. Supplemental balance sheet information related to operating leases is as follows: ($ in millions) December 31, 2021 December 31, 2020 Assets Other Assets $ 230 $ 31 Liabilities Accrued and other current liabilities 46 8 Other Noncurrent Liabilities 184 23 $ 230 $ 31 Weighted-average remaining lease term (years) 5.8 4.0 Weighted-average discount rate 3.3% 1.9% Maturities of operating lease liabilities as of December 31, 2021 are as follows: 2022 $ 53 2023 52 2024 46 2025 40 2026 15 Thereafter 46 Total lease payments $ 252 Less: Imputed interest 22 $ 230 As of December 31, 2021, the Company had entered into two real estate operating leases that had not yet commenced. The obligation associated with these leases totals $7.4 million.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company's financial condition, results of operations or cash flows. Given the nature of the litigation discussed in this note and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation, and (v) any other factors that may have a material effect on the litigation. The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. The Company's decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities. Reference is made below to certain litigation in which Merck, but not the Company, is named as a defendant. Pursuant to the Separation and Distribution Agreement, the Company is required to indemnify Merck for liabilities relating to, arising from, or resulting from such litigation. Product Liability Litigation Fosamax Merck is a defendant in product liability lawsuits in the United States involving Fosamax (alendronate sodium) (the "Fosamax Litigation"). As of December 31, 2021, approximately 3,470 cases comprising the Fosamax Litigation are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries ("Femur Fractures") in association with the use of Fosamax . All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey ("Femur Fracture MDL"). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck , the jury returned a verdict in Merck’s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck’s motion for judgment as a matter of law in the Glynn case and held that the plaintiff’s failure to warn claim was preempted by federal law. In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court's preemption decision in the Glynn case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit ("Third Circuit"). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court's opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs' state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court. Accordingly, as of December 31, 2021, approximately 975 cases were actively pending in the Femur Fracture MDL. As of December 31, 2021, approximately 2,215 cases alleging Femur Fractures have been filed in New Jersey state court and are pending in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed. As of December 31, 2021, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California. Additionally, there are four Femur Fracture cases pending in other state courts. Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Nexplanon/Implanon Merck is a defendant in lawsuits brought by individuals relating to the use of Implanon and Nexplanon . In the United States, as of December 31, 2021, there was one filed product liability action involving Nexplanon pending in Western District of Arkansas (in which Organon is also named as a defendant). In addition, there were two filed product liability actions involving Implanon , both of which are pending in the Northern District of Ohio as well as 56 unfiled cases involving Implanon alleging similar injuries, which have been tolled under a written tolling agreement. As of December 31, 2021, Merck had 20 cases pending outside the United States, of which 16 relate to Implanon and four relate to Nexplanon . Propecia/Proscar Merck is a defendant in product liability lawsuits in the United States involving Propecia (finasteride) and/or Proscar (finasteride). The federal lawsuits were consolidated for pretrial purposes in federal multidistrict litigation in the Eastern District of New York (the "MDL"), and the matters in state court in New Jersey were consolidated in Middlesex County ("N.J. Coordinated Proceedings"). In 2018, Merck and the Plaintiffs’ Executive Committee in the MDL and the Plaintiffs’ Liaison Counsel in the N.J. Coordinated Proceedings entered into an agreement to resolve the lawsuits for an aggregate amount of $4.3 million. The settlement was subject to certain contingencies, including 95% plaintiff participation and a per plaintiff clawback if the participation rate was less than 100%. The contingencies were satisfied and the settlement agreement has been finalized. At December 31, 2021, only three cases remain pending in the United States, including a case currently pending in the MDL, a matter involving Propecia in state court in Los Angeles, California and a matter involving Proscar in the United States District Court for the Eastern District of California. The Company is also defending 18 product liability cases outside the United States, two of which are class actions and four of which are putative class actions. Governmental Proceedings From time to time, the Company's subsidiaries may receive inquiries and may be the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required. Subject to certain exceptions specified in the Separation and Distribution Agreement, the Company assumed liability for all pending and threatened legal matters related to products transferred to the Company, including competition investigations resulting from enforcement activity concerning Merck’s conduct involving the Company's products. The Company could be obligated to indemnify Merck for fines or penalties, or a portion thereof, resulting from such investigations. The Company is aware of one such enforcement activity pending in Europe. Hadlima (adalimumab-bwwd) In July 2021, the Company received a Civil Investigation Demand ("CID") from the Office of the Attorney General for the State of Washington. The CID requests answers to interrogatories, as well as various documents, regarding certain activities related to adalimumab and adalimumab biosimilars. The Company is cooperating with the government’s investigation and intends to produce information and/or documents as necessary in response to the CID. Patent Litigation From time to time, generic manufacturers of pharmaceutical products file Abbreviated New Drug Applications ("ANDAs") with the U.S. Food and Drug Administration ("FDA") seeking to market generic forms of the Company's products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company's patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products, potential payment of damages and legal fees, and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges. Nexplanon In June 2017, Microspherix LLC ("Microspherix") sued the Company in the U.S. District Court for the District of New Jersey asserting that the manufacturing, use, sale and importation of Nexplanon infringed several of Microspherix's patents that claim radio-opaque, implantable drug delivery devices. Microspherix is claiming damages from September 2014 until the patents expired in May 2021. The Company brought Inter Partes Review ("IPR") proceedings in the United States Patent and Trademark Office ("USPTO") and successfully stayed the district court action. The USPTO invalidated some, but not all, of the claims asserted against the Company. The Company appealed the decisions that found claims valid, and the Court of Appeals for the Federal Circuit affirmed the USPTO’s decisions. The matter is no longer stayed in the district court, and the Company is currently litigating the invalidity and non-infringement of the remaining asserted claims. A claim construction hearing was held on March 2, 2022, and any further dates in the schedule will be set based on the date the court issues a claim construction order. Other Litigation There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company's financial condition, results of operations or cash flows either individually or in the aggregate. Legal Defense Reserves Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company's legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December 31, 2021 and December 31, 2020 of approximately $9 million and $35 million, respectively, represents the Company's best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The decrease in the legal defense reserves at December 31, 2021, as compared to December 31, 2020, is primarily attributable to reserves related to certain litigation that was retained by Merck under the Separation and Distribution Agreement. Accordingly, and in connection with the Separation adjustments, the reserve was adjusted to Net Investment from Merck in the Consolidated Financial Statements to reflect the Company's best estimate of its legal defense reserves as of December 31, 2021. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so. Environmental Matters In management's opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $24 million at both December 31, 2021 and December 31, 2020. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15 years. It is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation. Management also does not believe that these expenditures should result in a material adverse effect on the Company's financial condition, results of operations or liquidity for any year.

Stock-based Compensation Plans

Stock-based Compensation Plans	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation Plans	Stock-Based Compensation Plans In connection with the Separation, and in accordance with the Employee Matters Agreement, Organon's employees with outstanding former Merck stock-based awards received replacement stock-based awards under the 2021 Incentive Stock Plan at Separation. The ratio used to convert the Merck stock-based awards was designed to preserve the aggregate intrinsic value of the award immediately after the Separation when compared to the aggregate intrinsic value of the award immediately prior to Separation. Due to the conversion, Organon incurred $17 million of incremental stock-based compensation expense. Of this amount, $4 million was related to vested option awards and was recognized immediately into earnings in connection with the Separation, and the remainder is recognized ratably over the option awards' remaining weighted average vesting period of 2.66 years. At December 31, 2021, the unrecognized portion of the incremental stock-based expense was $9.7 million. In the second half of 2021, the Company granted stock option awards, performance share units and restricted share units under the 2021 Incentive Stock Plan. Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. Generally, stock options have a contractual term of ten years and vest one-third each year over a three-year period, subject to limited exceptions. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. RSU awards generally vest one-third each year over a three-year period. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company’s stock price. The terms of the Company's PSU awards allow the recipients of such awards to earn a variable number of shares based on total shareholder return of the Company relative to an index of peer companies ("relative TSR") specified in the awards. For PSUs with a market-based relative TSR goal, stock-based compensation expense is recognized based on the estimated fair value of the award at the grant date regardless of the actual number of shares earned. PSU awards generally vest after three years. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. Stock-based compensation expense incurred by the Company was as follows: ($ in millions) 2021 2020 2019 Stock-based compensation expense recognized in: Cost of sales $ 11 $ 17 $ 16 Selling, general and administrative 36 19 21 Research and Development 12 4 4 $ 59 $ 40 $ 41 Income tax benefits 12 8 9 As noted above, and in connection with the Separation, Merck's PSUs and RSUs were converted into 3.3 million Organon RSUs at a weighted average grant date fair value of $36.77 and Merck's stock options were converted into 4.1 million Organon stock options at a weighted average grant date fair value of $8.55. Stock options at Separation were valued using a combination of option models. The Company used the Black-Scholes model as the basis for the original fair value of the options, and the Hull-White I Lattice option pricing model calculated the incremental fair value. In applying these models, the Company used both historical data and current market data to estimate the fair value of its options. The Black-Scholes model assumptions include expected dividend yield, risk-free interest rate, volatility, and term of the options. The Hull-White I Lattice model requires several assumptions including expected exercise barrier, dividend yield, risk-free interest rate, remaining vesting life and remaining contractual life. These fair value assumptions were based on the awards and terms previously granted under the Merck incentive compensation plans to Organon employees. In connection with the stock options granted during 2021, the Company used the Black-Scholes model to determine the fair value of the stock options as of the grant date. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The expected dividend yield is based on forecasted patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using historical volatility. Due to the lack of trading history of Organon's stock at the time of valuation efforts, the historical component of expected volatility is based on historical monthly price changes of the peer group within the industry. Merck's historical data for Organon employees was used to estimate equity award exercise and employee termination behavior within the valuation model. The expected term represents the amount of time that options granted are expected to be outstanding based on historical and forecasted exercise behavior. The weighted average fair value of options was determined using the following assumptions: Year Ended December 31, 2021 Expected dividend yield 3.22 % Risk-free interest rate 0.92 % Expected volatility 45.80 % Expected term (years) 5.89 A summary of the transactions under the 2021 Incentive Stock Plan as of December 31, 2021 follows: Stock Options Restricted Share Units Performance Share Units (shares in thousands) Shares Weighted average exercise price Weighted average grant date fair value Shares Weighted average grant date fair value Shares Weighted average grant date fair value Outstanding as of June 2, 2021 4,097 $ 34.30 $ 8.55 3,311 $ 36.77 — $ — Granted 379 $ 35.38 $ 11.20 88 $ 34.72 120 $ 51.63 Vested/Exercised — $ — $ — (52) $ 38.46 — $ — Forfeited/Cancelled (82) $ 36.52 $ 9.05 (67) $ 36.55 — $ — Outstanding as of December 31, 2021 4,394 $ 34.35 $ 8.63 3,280 $ 36.69 120 $ 51.63 The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable at December 31, 2021: Equity Awards Vested and Expected to Vest Equity Awards That are Exercisable (shares in thousands; aggregate intrinsic value in millions) Awards Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Term Awards Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Term Stock Options 4,134 $ 34.35 $ 2 8.02 1,454 $ 30.66 $ 2 5.65 Restricted Share Units 3,051 — 100 1.99 — — — — Performance Share Units 102 — 4 2.63 — — — — The amount of unrecognized compensation costs as of December 31, 2021 was $109 million, which will be recognized in operating expense ratably over the weighted average vesting period of 2.08 years.

Pension and Other Postretiremen

Pension and Other Postretirement Benefit Plans	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefit Plans	Pension and Other Postretirement Benefit Plans Prior to the Separation on June 2, 2021, Organon participated in Merck's U.S. and non-U.S. plans. Merck has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. Merck also provides medical benefits, principally to its eligible U.S. retirees and their dependents, through its other postretirement benefit plans. The Company participated in Merck's benefit plans as though it was a participant in a multi-employer plan with the other businesses of Merck. The retirement benefits guidance provides that liabilities beyond any contributions currently due and unpaid are not required to be reported. Accordingly, no assets or liabilities associated with plans where the Company was a participant in a multi-employer plan with the other businesses of Merck have been reflected in the Company’s Consolidated Balance Sheet. The Consolidated Statement of Income includes expense allocations for these benefits, which were determined using a proportional allocation method. Total benefit plan expense allocated to the Company for the years ended December 31, 2021, 2020 and 2019 was $29 million, $55 million and $29 million, respectively. The Company's participation in the defined pension and postretirement benefit plans sponsored by Merck concluded upon the completion of the Separation on June 2, 2021. In accordance with the terms of the Employee Matter Agreement, prior to the Separation, Merck continued to provide service crediting to employees that transferred to Organon under Merck's U.S. defined benefit pension plan, supplemental executive retirement, and retiree medical plans for purposes of early retirement eligibility and subsidies, as well as for certain service crediting bridges. Although Merck is responsible for providing these benefits, Organon recorded the portion of the aggregate incremental cost of providing early retirement subsidies, service crediting bridges, and retiree health care benefits under these programs that is attributable to future service. Accordingly, upon Separation, the Company recorded a "grow-in" provision granted to employees transferred to Organon of $50 million, which represented the future service earned with Organon for these transferred employees for the pension and other postretirement benefits. The "grow-in" provision was recorded as an asset and will be expensed over the estimated average service period of eight years in operating expenses. The unamortized balance of the asset is $46 million as of December 31, 2021, of which $40 million is reflected in Other Assets and $6 million is reflected in Other current assets . As of June 2, 2021, Organon became the plan sponsor for certain non-U.S. defined benefit pension plans. These Consolidated Financial Statements reflect the periodic benefit costs and funded status of such plans. Organon pension plans are primarily comprised of plans in Switzerland, Belgium, Korea, Germany and Italy. The Company uses December 31 as the year-end measurement date for these plans. Net Periodic Benefit Cost The net periodic benefit cost for pension plans consisted of the following components: ($ in millions) 2021 2020 2019 Service cost $ 17 $ 4 $ 3 Interest cost 2 1 1 Expected return on plan assets (3) (1) (1) Net loss amortization 2 — — Net periodic benefit cost $ 18 $ 4 $ 3 The components of net periodic benefit cost other than the service cost component are included in Other (income) expense, net (see Note 15). Obligations and Funded Status Summarized information about changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows: ($ in millions) 2021 2020 Fair value of plan assets January 1 $ 40 $ 28 Actual return on plan assets 6 — Company contributions 19 4 Effects of exchange rate changes (6) 3 Benefits paid 2 (1) Other — 7 Net transfer of plan assets from Merck affiliates 56 (1) Fair value of plan assets December 31 $ 117 $ 40 Benefit obligation January 1 $ 76 $ 54 Service cost 17 4 Interest cost 2 1 Actuarial losses (17) 4 Benefits paid 2 (1) Effects of exchange rate changes (10) 6 Other — 6 Net transfer of benefit obligations from Merck affiliates 119 2 Benefit obligation December 31 $ 189 $ 76 Funded status December 31 $ (72) $ (36) Recognized as: Other assets $ 1 $ — Accrued and other current liabilities (1) — Other Noncurrent liabilities (72) (36) Information related to the funded status of materially significant pension plans at December 31 is as follows: ($ in millions) 2021 2020 Pension plans with a projected benefit obligation in excess of plan assets Projected benefit obligation $ 176 $ 76 Fair value of plan assets 104 38 Pension plans with an accumulated benefit obligation in excess of plan assets Accumulated benefit obligation $ 154 $ 54 Fair value of plan assets 97 38 Plan Assets Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measured fair value with Level 1 having the highest priority and Level 3 having the lowest. Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; Level 3 - Unobservable inputs that are supported by little or no market activity. The level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgement or estimation. If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The fair values of the Company’s pension plan assets at December 31 by asset category are as follows: Fair Value Measurements Using Fair Value Measurements Using Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 2021 2020 Cash and cash equivalents $ 3 $ — $ — $ 3 $ — $ — $ — $ — Investment funds Developed markets equities 28 3 — 31 — — — — Government and agency obligations 21 1 — 22 — — — — Emerging markets equities 5 — — 5 — — — — Other 3 1 — 4 — — — — Equity income securities Developed markets equities 1 — — 1 — — — — Fixed income securities Government and agency obligations — 3 — 3 — 5 — 5 Corporate Obligations — 2 — 2 — — — — Other investments Insurance contracts — 33 — 33 — 34 — 34 Other 12 1 — 13 — 1 — 1 Plan assets at fair value $ 73 $ 44 $ — $ 117 $ — $ 40 $ — $ 40 The targeted investment portfolio for the Company’s pension plans that are sponsored outside the United States varies based on the duration of pension liabilities and local government rules and regulations. There are no unfunded commitments or redemption restrictions related to these investments. Expected Contributions Expected contributions during 2022 are approximately $9 million for the Company's pension plans. Expected Benefit Payments Expected benefit payments are follows: 2022, $6 million; 2023, $8 million; 2024, $7 million; 2025, $6 million; 2026, $7 million; 2027-2031, $41 million. Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service. Amounts Recognized in Other Comprehensive Income Net loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. ($ in millions) 2021 2020 2019 Net gain (loss) arising during the period $ 4 $ 6 $ (5) Net loss amortization included in benefit cost 2 — — Actuarial Assumptions The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining pension plan information are as follows: ($ in millions) 2021 2020 2019 Net periodic benefit cost Discount rate 1.48 % 3.91 % 4.14 % Expected rate of return on plan assets 4.50 % 2.62 % 3.08 % Salary growth rate 3.18 % 3.63 % 3.36 % Benefit obligation Discount rate 1.49 % 1.52 % 1.63 % Salary growth rate 2.75 % 3.63 % 3.33 % The discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality, fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan’s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. Savings Plan Prior to June 2, 2021, the Company participated in certain Merck defined contribution savings plans. After the Separation, Organon maintains a defined contribution savings plan in the United States. The Company matches a percentage of employees’ contributions consistent with the provisions of the plan. In addition, since Separation, the Company makes retirement contributions calculated based on a predetermined formula that considers years of service and the employee's age. Total allocated and actual employer contributions to this plan in 2021 were $23 million. The amount allocated for total employer contributions in 2020 and 2019 was $18 million for both periods.

Other (Income) Expense, Net

Other (Income) Expense, Net	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
Other (Income) Expense, Net	Other (Income) Expense, Net Other (income) expense, net, consisted of: ($ in millions) 2021 2020 2019 Exchange (gains) losses $ 4 $ 44 $ 73 Interest expense 258 — — Other, net 17 (9) (7) $ 279 $ 35 $ 66

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Taxes on Income	Taxes on Income A reconciliation between the effective tax rate and the U.S. statutory rate is as follows: 2021 2020 2019 ($ in millions) Amount Tax Rate Amount Tax Rate Amount Tax Rate U.S. statutory rate applied to income before taxes $ 321 21.0 % $ 578 21.0 % $ 776 21.0 % Differential arising from: Foreign earnings (43) (2.8) (93) (3.4) (143) (3.9) Tax settlements (32) (2.1) — — (264) (7.1) Amortization of intangible assets (75) (4.9) 12 0.4 22 0.6 State taxes (3) (0.2) — — 5 0.1 Global Intangible Low-Taxed Income 17 1.1 — Other (7) (0.4) (1) — (6) (0.1) $ 178 11.7 % $ 496 18.0 % $ 390 10.6 % For the first five months of 2021 and the years ended December 31, 2020 and 2019, income taxes were calculated as if the Company filed income tax returns on a standalone basis. For those years, the Company believes the assumptions supporting its allocation and presentation of income taxes on a separate return basis are reasonable. The Company has no remaining transition tax liability as of December 31, 2021 under the Tax Cuts and Jobs Act ("TCJA) that was enacted in 2017. The transition tax liability was $1.5 billion at December 31, 2020, of which $161 million was included in Income Taxes Payable and the remainder of $1.3 billion was included in Other Noncurrent Liabilities . As a result of the TCJA, the Company has made a determination it is no longer indefinitely reinvested with respect to a majority of its previously taxed undistributed earnings from foreign subsidiaries and provided for a deferred tax liability for withholding taxes due upon future remittances, net of certain foreign income tax credits. At December 31, 2021, the deferred income tax liabilities on undistributed earnings for certain subsidiaries that are deemed indefinitely reinvested is immaterial. The tax effects of foreign earnings in the tax rate reconciliation above primarily reflect the effects of operations in jurisdictions with different tax rates than the United States thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The favorable impact is primarily attributable to a new reduced tax rate arrangement that was agreed to in Switzerland for a newly active legal entity. The effective income tax rates were 11.7%, 18.0% and 10.6% for 2021, 2020 and 2019, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings. During 2021, the Company recorded a $75 million tax benefit relating to a portion of the non-U.S. step-up of tax basis associated with the Company's Separation from Merck. The effective income tax rate for 2021 also reflects the Internal Revenue Service ("IRS") conclusion of its examinations of Merck’s 2015-2016 U.S. federal income tax returns as further detailed below. Income before taxes consisted of: ($ in millions) 2021 2020 2019 Domestic $ (96) $ 532 $ 564 Foreign 1,625 2,220 3,132 $ 1,529 $ 2,752 $ 3,696 Taxes on income consisted of: ($ in millions) 2021 2020 2019 Current provision Federal $ 41 $ 91 $ (126) Foreign 435 435 549 State (10) 2 (45) $ 466 $ 528 $ 378 Deferred provision Federal $ (64) $ 11 $ 3 Foreign (220) (44) (10) State (4) 1 19 $ (288) $ (32) $ 12 $ 178 $ 496 $ 390 Deferred income taxes at December 31 consisted of: 2021 2020 ($ in millions) Assets Liabilities Assets Liabilities Product intangibles and licenses $ 105 $ — $ 24 $ — Inventory related 15 — — 18 Reserves and allowances 40 — 39 — Accrued expenses 23 — — — Accelerated depreciation — 15 — — Unremitted foreign earnings — 2 — 78 Right of use asset 51 — — — Lease liability — 51 — — Interest expense limitation carryforward 23 — — — Compensation related 23 — — — Unrecognized tax benefits — — 18 — Hedging — 36 — — Net operating losses and other tax credit carryforwards 103 — 70 — Other 24 — 36 — Subtotal $ 407 $ 104 $ 187 $ 96 Valuation allowance (35) — (69) — Total deferred taxes $ 372 $ 104 $ 118 $ 96 Net deferred income taxes $ 268 $ 22 Recognized as: Other Assets $ 272 $ 150 Deferred Income Taxes $ 4 $ 128 The Company has recognized $103 million and $70 million deferred taxes on net operating loss (NOL) carryforwards in multiple jurisdictions as of December 31, 2021 and 2020, respectively. Valuation allowances of $35 million have been established on certain foreign deferred tax assets. During 2021, the Company reduced valuation allowances by $42 million as a result of the Separation. Income taxes paid in 2021 were $131 million. Income taxes paid by Merck with respect to Organon for 2020 and 2019 were $416 million and $1.1 billion, respectively. As of December 31, 2021, and 2020, the Company deferred the income tax consequences resulting from intra-entity transfers of inventory totaling $377 million and $421 million, respectively. These amounts are reflected in Other current assets. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: ($ in millions) 2021 2020 2019 Balance January 1 $ 219 $ 213 $ 619 Additions related to current year tax positions 23 15 12 Additions related to prior year tax positions 18 23 4 Reductions for tax positions of prior years (1) (49) (3) (274) Spinoff related adjustments (2) (108) — — Settlements (15) (19) (140) Lapse of statute of limitations (10) (10) (8) Balance December 31 $ 78 $ 219 $ 213 (1) Amounts in 2019 reflect the settlement with the IRS discussed below. (2) Unrecognized tax benefits were reduced by $108 million in 2021 related to positions taken prior to the spinoff for which Merck, as the Company’s former Parent, is the primary obligor and is responsible for settlement and payment of any resulting tax obligation. If the Company were to recognize the unrecognized tax benefits of $78 million, at December 31, 2021, the income tax provision would reflect a favorable net impact of $78 million. Prior to June 2, 2021, the Company was part of Merck’s consolidated U.S. federal income tax return, as well as separate and combined Merck income tax returns in numerous state and international jurisdictions. Merck was under examination by numerous tax authorities in various jurisdictions globally. During 2021, the IRS concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company reflected an allocation from Merck of $18 million representing the Company's portion of the payment made to the IRS in the Consolidated Financial Statements. The Company's portion of reserves for unrecognized tax benefits for the years under examination exceeded the allocated adjustments relating to this examination period and therefore the Company included a $29 million net tax benefit for the year ended December 31, 2021. This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination. The Company is subject to income tax in the United States (federal, state and local) as well as other jurisdictions outside of the United States in which we operate. As part of the Separation from Merck, $79.3 million of liabilities for unrecognized tax benefits associated with uncertain tax positions for jurisdictions outside of the United States were conveyed to Organon. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December 31, 2021 could decrease by up to $11 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. Interest and penalties associated with uncertain tax positions were immaterial in 2021 and resulted in an expense (benefit) of $11 million in 2020 and $(48) million in 2019, respectively. These amounts reflect the beneficial impacts of various tax settlements, including those discussed below. Liabilities for accrued interest and penalties were $39 million and $68 million as of December 31, 2021 and 2020, respectively. In 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company reflected a payment of $142 million in the consolidated financial statements. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a net tax benefit of $258 million in 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for. Various state and foreign tax examinations are in progress and for these jurisdictions, income tax returns are open for examination for the period 2006 through 2021.

Other Comprehensive Income (Los

Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss) Changes in Accumulated other comprehensive loss by component are as follows: ($ in millions) Employee Cumulative Accumulated Other Balance at January 1, 2019, net of taxes $ (294) $ (614) $ (908) Other comprehensive income (loss), pretax (68) 54 (14) Tax 8 — 8 Other comprehensive income (loss), net of taxes (60) 54 (6) Balance at December 31, 2019, net of taxes $ (354) $ (560) $ (914) Other comprehensive income (loss), pretax (172) (30) (202) Tax 29 — 29 Other comprehensive income (loss), net of taxes (143) (30) (173) Net Transfer of benefit plans to Merck affiliates $ 465 $ — $ 465 Balance at December 31, 2020, net of taxes $ (32) $ (590) $ (622) Other comprehensive income (loss), pretax 21 90 111 Tax (13) — (13) Other comprehensive income (loss), net of taxes 8 90 98 Net transfer of benefit plans to Merck affiliates 11 — 11 Balance at December 31, 2021, net of taxes $ (13) $ (500) $ (513)

Product and Geographic Informat

Product and Geographic Information	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Product and Geographic Information	Product and Geographic InformationThe Company’s operations include the following product portfolios, which constitute one operating segment engaged in developing and delivering innovative health solutions through its portfolio of prescription therapies within women’s health, biosimilars and established brands. Revenue of the Company’s products were as follows: 2021 2020 2019 ($ in millions) U.S. Int’l Total U.S. Int’l Total U.S. Int’l Total Women’s Health Nexplanon/Implanon NXT $ 532 $ 237 $ 769 $ 488 $ 192 $ 680 $ 568 $ 219 $ 787 Follistim AQ 110 127 237 84 108 193 103 138 241 NuvaRing 85 106 191 111 126 236 744 134 879 ganirelix acetate injection 22 88 111 11 69 81 25 86 112 Cerazette — 70 70 — 67 67 — 71 71 Other Women's Health (1) 96 139 234 165 133 298 18 156 173 Biosimilars Renflexis 164 21 186 123 12 135 95 1 96 Ontruzant 34 92 126 3 113 115 — 83 83 Brenzys — 63 63 — 74 74 — 72 72 Other Biosimilars (1) — 49 49 — 6 6 — — — Established Brands Cardiovascular Zetia 10 368 378 (1) 483 482 14 575 590 Vytorin 11 153 164 12 170 182 16 268 285 Atozet — 458 458 — 453 453 — 391 391 Rosuzet — 68 68 — 130 130 — 120 120 Cozaar/Hyzaar 12 345 357 21 365 386 25 417 442 Zocor 4 61 65 3 75 77 6 107 112 Other Cardiovascular (1) — 126 126 — 162 162 — 134 134 Respiratory Singulair 15 398 413 18 444 462 30 669 698 Nasonex 4 201 206 12 206 218 9 284 293 Dulera 154 36 190 188 34 222 189 29 217 Clarinex 6 106 111 7 123 130 8 133 142 Asmanex 57 7 63 76 8 83 84 9 94 Other Respiratory (1) — 26 26 3 32 35 1 25 25 Non-Opioid Pain, Bone and Dermatology Arcoxia — 244 244 — 258 258 — 288 288 Fosamax 4 172 175 4 176 180 9 188 197 Diprospan — 125 125 — 118 118 — 102 102 Diprosone 1 86 87 1 82 83 1 83 84 Other Non-Opioid Pain, Bone and Dermatology (1) 15 183 199 9 186 195 14 199 214 Other Proscar 1 116 117 2 174 176 2 202 203 Propecia 9 127 136 10 119 129 11 120 131 Sinemet — 71 71 (1) 78 77 1 78 79 Remeron 3 62 66 2 61 64 3 79 82 Other (1) 37 185 223 53 185 238 62 176 238 Other (2) (3) 205 200 4 102 107 (17) 120 102 Total Revenue $ 1,383 $ 4,921 $ 6,304 $ 1,408 $ 5,124 $ 6,532 $ 2,021 $ 5,756 $ 7,777 U.S. plus international may not equal total due to rounding . (1) Includes sales of products not listed separately. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health. (2) Includes manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation. Combined sales by geographic area where derived are as follows: ($ in millions) 2021 2020 2019 Europe and Canada $ 1,741 $ 1,726 $ 1,893 United States 1,383 1,408 2,021 Asia Pacific and Japan 1,173 1,535 1,789 China 933 873 1,027 Latin America, Middle East, Russia and Africa 841 857 923 Other (1) 233 133 124 $ 6,304 $ 6,532 $ 7,777 (1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation. During 2021, the Company realigned its geographic presentation of sales to reflect the internal management view of Organon as a standalone entity. Accordingly, prior period sales by geographic area have been recast to reflect these changes. Approximately 80% of the Company's long-lived assets is located in Europe and Canada, and 10% in the United States. The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.

Third Party Arrangements and Re

Third Party Arrangements and Related Party Disclosures	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Third Party Arrangements and Related Party Disclosures	Third-Party Arrangements and Related Party Disclosures Pursuant to the Separation, Merck ceased to be a related party to Organon and accordingly, no related party transactions or balances are reported since June 2, 2021. In connection with the Separation, the Company entered into the Separation and Distribution Agreement, which contains provisions that, among other things, relate to (i) assets, liabilities and contracts to be transferred, assumed and assigned to each of Organon and Merck as part of the Separation, (ii) cross-indemnities principally designed to place financial responsibility for the obligations and liabilities of Organon business with Organon and financial responsibility for the obligations and liabilities of Merck’s remaining business with Merck, (iii) procedures with respect to claims subject to indemnification and related matters, (iv) the allocation among Organon and Merck of rights and obligations under existing insurance policies with respect to occurrences prior to completion of the Distribution, as well as the right to proceeds and the obligation to incur certain deductibles under certain insurance policies, and (v) procedures governing Organon’s and Merck’s obligations and allocations of liabilities with respect to ongoing litigation matters that may implicate each of Merck’s business and Organon’s business. Agreements that Organon entered into with Merck that govern aspects of Organon’s relationship with Merck following the Separation include: • Transition Services Agreements - Under the TSA, (i) Merck and certain of its affiliates provide Organon and certain of its affiliates, on an interim, transitional basis, various services, and (ii) Organon and certain of its affiliates provide Merck and certain of its affiliates, on an interim, transitional basis, various services. The services provided by Merck will include, among others, information technology, human resources, finance, quality, regulatory, supply chain management, promotional services, distribution services and certain other services, and will provide on a cost or, where applicable, a cost-plus basis. The Merck services generally commenced on the date of the Separation and generally terminate within 25 months following the date of Separation. Organon generally has the right to request the early termination of any or all services with advance notice. The services provided by Organon include quality, regulatory, supply chain management, promotional services, distribution services and certain other services and is provided on a cost or, where applicable, a cost-plus basis. The provisions of Organon services under the TSA generally commenced on the date of Separation and terminate within 25 months following the Separation. Merck will generally have the right to request the early termination of any or all services with advance notice. • Interim Operating Agreements - Merck and Organon entered into a series of interim operating model ("IOM") agreements pursuant to which Merck and certain of its affiliates that held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products in various jurisdictions prior to the Separation will continue to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon or its affiliates, while permitting Organon (or Merck, as applicable) to recognize revenue relating to the sale of its respective products, to the extent practicable. Under such interim operating agreements and in accordance with the Separation and Distribution Agreement, the relevant Merck entity will continue operations in the affected market on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Organon began receiving these economic benefits as of June 2, 2021. Based on the terms of the IOM agreement, the Company determined it is the Principal under this arrangement. Organon holds all risks, and rewards of ownership inclusive of risk of loss, market risk and benefits related to the inventory. Additionally, Organon has latitude in pricing, has the ability to direct Merck regarding decisions over inventory, and is responsible for all credit and collections risks and losses associated with the related receivables. As such, Organon recognizes these sales on a gross basis. Certain amounts are estimates and subject to possible adjustment in future periods. • Manufacturing and Supply Agreements - Merck and Organon and/or their applicable affiliates entered into a number of manufacturing and supply agreements pursuant to which the relevant Merck entity will (a) manufacture and supply certain active pharmaceutical ingredients for the relevant Organon entity, (b) toll manufacture and supply certain formulated pharmaceutical products for such Organon entity, and (c) package and label certain finished pharmaceutical products for such Organon entity. Similarly, the relevant Organon entity will (a) manufacture and supply certain formulated pharmaceutical products for the relevant Merck entity, and (b) package and label certain finished pharmaceutical products for such Merck entity. • Tax Matters Agreement - The TMA allocates responsibility for all U.S. federal income, state and foreign income, franchise, capital gain, withholding and similar taxes, as well as all non-income taxes. The TMA also provides for cooperation between Merck and Organon with respect to tax matters, the exchange of information and the retention of records that may affect the tax liabilities of the parties to the TMA. Merck generally is responsible for any income taxes reportable on an originally filed consolidated, combined or unitary return that includes Merck or any of its subsidiaries (and Organon and/or any of its subsidiaries) for any periods or portions thereof ending on or prior to the Distribution. Organon generally is responsible for any income taxes that are reportable on originally filed returns that include only Organon and/or any of its subsidiaries, for all tax periods. Additionally, as a general matter, Merck is responsible for certain income and non-income taxes imposed as the direct result of the Separation or of an internal separation transaction. Organon is responsible for certain taxes that exclusively relate to Organon’s business and for taxes resulting from any breach of certain representations or covenants that Organon made in the TMA. The TMA imposes restrictions on Organon and its subsidiaries during the two-year period following the Distribution. The restrictions are intended to prevent the Distribution and certain related transactions from failing to qualify as tax-free for U.S. federal income tax purposes. During such period, Organon and its subsidiaries generally are prohibited from, among other things, entering into transactions in which all or a portion of the shares of the Common Stock would be acquired or all or a portion of certain assets of Organon and its subsidiaries would be acquired. Organon and its subsidiaries also are prohibited, during such period, from merging or consolidating with any other person, issuing equity securities beyond certain thresholds, and repurchasing Common Stock other than in certain open-market transactions. Certain amounts are estimates and subject to possible adjustment in future periods. • Employee Matters Agreement - The agreement allocated assets, liabilities and responsibilities relating to employee compensation and benefit plans and programs and other related matters in connection with the Separation. • Other agreements that Organon entered into with Merck include the Intellectual Property License Agreements and Regulatory Agreements. The amount due from Merck under the above agreements was $403 million at December 31, 2021 and is reflected in accounts receivable. The amount due to Merck under these agreements was $928 million at December 31, 2021 and is included in accounts payable. For the period post-Separation through December 31, 2021, sales and cost of sales resulting from the manufacturing and supply agreements with Merck were $90 million and $85 million, respectively. Following the distribution to Merck of $9.0 billion in net debt proceeds (see Note 11) and settlement of certain balances with Merck and its affiliates, the balance in cash and cash equivalents included approximately $400 million of funds received from Merck for the purchase of inventory from Merck upon exit of certain IOMs. The purchase was complete by the end of 2021. Prior to the Separation, the Company did not operate as a standalone business and the Consolidated Financial Statements were derived from the consolidated financial statements and accounting records of Merck. The following disclosure summarizes activity between the Company and Merck up to the Separation, including the affiliates of Merck that were not part of the Separation. Cost allocations from Merck Merck provided significant corporate, manufacturing, selling, marketing, administrative, research services and resources to the Company. Some of these services continue to be provided by Merck to the Company on a temporary basis under the Transition Services Agreement. The Consolidated Financial Statements reflect an allocation of these costs. See Note 2 for a discussion of these costs and the methodology used to allocate them. The allocations reflected in the Consolidated Statement of Income for continuing operations are as follows: ($ in millions) 2021 (1) 2020 2019 Cost of sales $ 69 $ 452 $ 520 Selling, general and administrative 134 658 725 Research and development 35 152 190 $ 238 $ 1,262 $ 1,435 (1) Includes costs through the Separation Date. Management believes these cost allocations are a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Company during the periods presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company operated as a standalone public company at the time. Actual costs that may have been incurred if the Company had been a standalone public company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Company’s employees and strategic decisions made in areas such as manufacturing, selling, information technology and infrastructure. Related party transactions The following transactions represent activity between Organon Entities and Transferred Entities with other Merck affiliates prior to the Separation: ($ in millions) 2021 2020 2019 Included in continuing operations Supply sales to Merck affiliates $ 143 $ 57 $ — Purchases from Merck affiliates 65 657 — Cost reimbursements and fees from Merck affiliates 1 — — Included in discontinued operations Supply sales to Merck affiliates $ 12 $ 542 $ 501 Purchases from Merck affiliates 53 382 1,087 Cost reimbursements and fees (to) from Merck affiliates $ — $ 22 $ 19 Interest expense, net on loans and advances with Merck affiliates $ — $ 2 $ 3 The Company had the following balances with Merck affiliates: ($ in millions) December 31, 2020 Included in continuing operations Short term borrowings, net $ 1,512 Trade payables (receivables), net (173) Due to related party $ 1,339 Included in discontinued operations Short term loans receivables, net $ 247 Short term notes payable, net (25) Trade payables, net (33) Due from related party $ 189 Net transfers to Merck & Co., Inc. Prior to the Separation, net transfers to Merck were included within Net investment from Merck & Co., Inc. on the Consolidated Statement of Equity and represent the net effect of transactions between the Company and Merck. The components of Net transfers to Merck & Co., Inc. were as follows: ($ in millions) 2021 (1) 2020 2019 Cash pooling and general financing activities $ 168 $ 5,216 $ 5,310 Cost allocations, excluding non-cash stock-based compensation (209) (1,222) (1,394) Taxes deemed settled with Merck (259) (409) (1,039) Allocated derivative and hedging (losses) gains (88) (51) 55 Net transfers (from) to Merck & Co., Inc. as reflected in the Consolidated Statement of Cash Flows for Continuing Operations (2) $ (388) $ 3,534 $ 2,932 Net transfers to (from) Merck included in Net Cash Provided by (Used in) Discontinued Operations 597 (194) (355) Total net transfers to Merck as included in the Consolidated Statement of Cash Flows $ 209 $ 3,340 $ 2,577 Stock-based compensation expense (includes $3 and $7 of discontinued operations for 2021 and 2020, respectively) (32) (54) (52) Net assets (distributed to) contributed by Merck affiliates (778) 250 — Recognition of amounts in Accumulated other comprehensive loss related to employee benefit plan transfers to Merck affiliates 13 465 — Net transfers (from) to Merck & Co., Inc. as reflected in the Consolidated Statement of Equity $ (588) $ 4,001 $ 2,525 (1) The amounts for the year ended December 31, 2021 represent activity through the date of the Separation. (2) Net transfers (from) to Merck & Co., Inc. as reflected in the Consolidated Statement of Cash Flows for Continuing Operations for the year ended December 31, 2021 include Separation adjustments of $52 million, identified after the date of the Separation. Refer to Note 2 for further details. Prior to the Separation, transfers between the Organon Entities, the Transferring Entities and Merck affiliates were recognized in Net transfers to Merck & Co., Inc . in the Consolidated Statement of Equity at Merck’s historical cost (see Note 2). Additionally, in connection with the Separation, certain assets and liabilities included in the pre-Separation balance sheet were retained by Merck and certain assets and liabilities not included in the pre-Separation balance sheet were transferred to Organon. Separation-related adjustments were also recognized in Net transfers to Merck & Co., Inc. Adjustments for transfers and separations are reflected in the Company's Consolidated Financial Statements for the year ended December 31, 2021 and were comprised of (i) the retention of assets and liabilities by Merck affiliates including accounts receivable, net of $751 million, inventories of $265 million, transition tax liabilities of $1.4 billion and certain liabilities net of other assets of $210 million, partially offset by (ii) the contribution of assets and liabilities to Organon Entities from Merck affiliates, including assets of $59 million and liabilities of $35 million. Merck conveyed to Organon $79.3 million of reserves for unrecognized tax benefits associated with uncertain tax positions for jurisdictions outside of the United States. See Note 16 for further details. The Company also incurred costs related to employee matters in connection with the Separation, primarily related to stock-based and pension related compensation costs. See Notes 13 and 14 for further details.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued OperationsIn contemplation of the Separation, the Merck Retained Products business in the Transferred Entities was distributed to Merck affiliates and, accordingly, the historical results of operations, assets and liabilities, and the cash flows of the Merck Retained Products for such Transferred Entities are reflected as discontinued operations. The components of Income (loss) from discontinued operations, net of tax for the Merck Retained Products business are as follows: ($ in millions) 2021 2020 2019 Sales $ 93 $ 1,564 $ 1,753 Costs, Expenses and Other Cost of Sales 65 1,228 1,347 Selling, general and administrative 15 310 479 Research and development 4 94 112 Restructuring costs — 10 23 Other (income) expense, net 4 (6) (67) Income (loss) from discontinued operations before taxes $ 5 $ (72) $ (141) Taxes on income 5 24 (53) Loss from discontinued operations, net of taxes $ — $ (96) $ (88) Discontinued operations includes related party sales of $12 million, $542 million and $501 million for the year ended December 31, 2021, 2020 and 2019, respectively. Costs for inventory purchases from related parties was $53 million, $382 million, and $1.1 billion for the year ended December 31, 2021, 2020 and 2019, respectively. The components of assets and liabilities of discontinued operations that are stated separately as of December 31, 2020 in the Consolidated Balance Sheets are comprised of the following items: ($ in millions) December 31, 2020 Assets Cash and cash equivalents $ 58 Accounts receivable 322 Inventories 58 Due from related party 189 Other current assets 47 Total current assets of discontinued operations 674 Property, Plant and Equipment, net 14 Other Noncurrent Assets 77 Total Noncurrent Assets of Discontinued Operations 91 Total Assets of Discontinued Operations $ 765 Liabilities Trade accounts payable $ 35 Accrued and other current liabilities 93 Total current liabilities of discontinued operations 128 Deferred Income Taxes — Other Noncurrent Liabilities 83 Total Noncurrent Liabilities of Discontinued Operations 83 Total Liabilities of Discontinued Operations $ 211

Earnings per Share

Earnings per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings per Share	Earnings per ShareOn June 2, 2021, the date of the Separation, 253,516,000 shares of the Common Stock were distributed to Merck stockholders of record as of the Record Date. This share amount is utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Separation. For the 2020 and 2019 calculations, these shares are treated as issued and outstanding at January 1, 2020 and 2019 for purposes of calculating historical basic and diluted earnings per share. Prior to the Separation, certain of the Company's employees participated in stock-based compensation plans sponsored by Merck. Under these plans employees were granted stock options, performance share units ("PSUs"), and restricted stock units ("RSUs"). On June 2, 2021, and in accordance with the Employee Matters Agreement, all Merck stock options, PSUs and RSUs were converted using the conversion ratios set forth in the Employee Matters Agreement. Merck stock options, PSUs and RSUs were converted into Organon RSUs and option awards. Awards were equitably adjusted to reflect the spinoff and to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments (see Note 13 for additional details). The calculation of basic and diluted earnings per common share for the year ended December 31, 2021, 2020 and 2019 was as follows: ($ in millions and shares in thousands, except per share amounts) 2021 2020 2019 Net income attributable to Organon: Income from continuing operations $ 1,351 $ 2,256 $ 3,306 Income from discontinued operations — (96) (88) Net income attributable to Organon $ 1,351 $ 2,160 $ 3,218 Basic weighted average number of shares outstanding 253,538 253,516 253,516 Stock awards and equity units (share equivalent) 655 — — Diluted weighted average common shares outstanding 254,193 253,516 253,516 Earnings (Loss) Per Share Attributable to Organon common stockholders - Basic Income from continuing operations $ 5.33 $ 8.90 $ 13.04 Loss from discontinued operations — (0.38) (0.35) Basic earnings per common share attributable to Organon common stockholders $ 5.33 $ 8.52 $ 12.69 Earnings (Loss) Per Share Attributable to Organon common stockholders - Diluted Income from continuing operations 5.31 8.90 13.04 Loss from discontinued operations — (0.38) (0.35) Diluted earnings per common share attributable to Organon common stockholders $ 5.31 $ 8.52 $ 12.69 For periods prior to the Separation, it is assumed that there were no dilutive equity instruments as there were no equity awards of Organon outstanding prior to the Separation. For periods subsequent to the Separation and the Distribution, diluted earnings per share is computed by giving effect to all potentially dilutive stock awards that are outstanding. The computation of diluted earnings per share excludes the effect of the potential exercise of stock-based awards, when the effect of the potential exercise would be anti-dilutive. The weighted-average number of common shares outstanding for basic and diluted earnings per share for the year ended December 31, 2021 was based on the weighted-average number of common shares outstanding for the period beginning after the Distribution date. For 2021, 4.9 million of common shares issuable under stock-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive. Dividend Program During the second and third quarters of 2021, the Company's Board of Directors declared a quarterly cash dividend $0.28 per share on Organon's Common Stock that was paid on September 13 and December 16, 2021, respectively, to stockholders of record at the close of business on August 23, and November 22, 2021, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsIn February 2022, Organon acquired the product rights from Bayer AG to Marvelon® and Mercilon®, combined oral hormonal daily contraceptive pills, in the People’s Republic of China, including Hong Kong and Macau, and has entered into an agreement to acquire the rights to these products in Vietnam. Marvelon and Mercilon are already owned, manufactured, and marketed by Organon as prescription oral contraceptives in 20 other markets. The transaction to acquire the rights to these products in Vietnam will close in the first half of 2022 and is subject to customary closing conditions, including regulatory approval.

Summary of Accounting Policies

Summary of Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting	On June 2, 2021, the Company became a standalone publicly traded company, and its financial statements are now presented on a consolidated basis. Prior to the Separation on June 2, 2021, the Company’s historical combined financial statements were prepared on a standalone basis and were derived from Merck’s consolidated financial statements and accounting records. The financial statements for all periods presented, including the historical results of the Company prior to June 2, 2021, are now referred to as "Consolidated Financial Statements", and have been prepared pursuant to the rules and regulations for reporting on Form 10-K. Periods Prior to Separation The assets, liabilities, revenue and expenses of the Company were reflected in the Consolidated Financial Statements on a historical cost basis, as included in the consolidated financial statements of Merck, using the historical accounting policies applied by Merck. The Consolidated Financial Statements did not purport to reflect what the Company’s results of operations, comprehensive income, financial position, equity or cash flows would have been had the Company operated as a standalone public company during the periods presented. The Consolidated Financial Statements were prepared following a legal entity approach, which resulted in the inclusion of the following: • Certain assets and liabilities, results of operations and cash flows attributable to the sales of Organon Products that were contributed to Organon prior to the consummation of the Separation. • The Transferred Entities, which have historically included the results from the sales of both Organon Products and the Merck Retained Products. Each Transferred Entity’s historical operations, including its results of operations, assets and liabilities, and cash flows have been fully reflected in the Consolidated Financial Statements. • In contemplation of the Separation, the Merck Retained Products business of the Transferred Entities was distributed to Merck and its affiliates ("MRP Distribution") and, accordingly, the historical results of operations, assets and liabilities, and the cash flows of the Merck Retained Products for such Transferred Entities are reflected as discontinued operations. The Company’s businesses had historically functioned together with the other businesses controlled by Merck. Accordingly, the Company relied on Merck’s corporate and other support functions for its business. Therefore, for the period prior to the Separation, certain corporate and shared costs were allocated to the Company based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method, including: (i) expenses related to Merck support functions, including expenses for facilities, executive oversight, treasury, finance, legal, human resources, shared services, compliance, procurement, information technology and other corporate functions. (ii) certain manufacturing and supply costs incurred by Merck’s manufacturing division, including facility management, distribution, logistics, planning and global quality. (iii) certain costs incurred by Merck’s human health division in relation to selling and marketing activities, and related administrative support functions, that are not routinely allocated to therapeutic areas. (iv) certain costs incurred by Merck’s research laboratories for activities related to drug discovery and development, as well as medical and regulatory affairs. (v) restructuring costs (see Note 6) and stock-based compensation expenses (see Note 13); and (vi) certain compensation expenses maintained on a centralized basis such as certain employee benefit expenses. Management believes these cost allocations were a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Company during the period prior to the Separation, though the allocations may not be indicative of the actual costs that would have been incurred had the Company operated as a standalone public company. Actual costs that may have been incurred if the Company had been a standalone company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Company’s employees, and strategic decisions made in areas such as manufacturing, selling and marketing, research and development, information technology and infrastructure. Merck maintains various employee benefit plans in which the Company’s employees participated during periods prior to the Separation, and a portion of the costs associated with these plans was included in the Company’s Consolidated Financial Statements. The Consolidated Balance Sheet at December 31, 2020 only includes assets and liabilities relating to plans for which the entity being transferred was the plan sponsor. Certain pension assets and obligations were transferred by Merck into legal entities established to operate the Organon Products business (the "Organon Entities") that are the plan sponsor and, accordingly, the Consolidated Balance Sheet at December 31, 2021 includes assets and liabilities of the newly established plans of Organon. Merck utilized a centralized approach to cash management and the financing of its operations. Cash generated by the Company was routinely transferred into accounts managed by Merck’s centralized treasury function and cash disbursements for the Company’s operations prior to the Separation were funded as needed by Merck. Cash and cash equivalents of the Organon Entities and the Transferred Entities were reflected in the Company’s Consolidated Balance Sheet. Balances held by the Organon Entities and the Transferred Entities with Merck for cash transfers and loans were reflected as Due to related party prior to Separation. All other cash, cash equivalents, short-term investments and related transfers between Merck and the Company were generally held centrally through accounts controlled and maintained by Merck and were not specifically identifiable to the Company. Accordingly, such balances were accounted for through Net investment from Merck & Co., Inc . Merck’s third-party debt and related interest expense were not attributed to the Company because the Company was not the legal obligor of the debt and the borrowings were not specifically identifiable to the Company. For the Organon Entities and the Transferred Entities, transactions with Merck affiliates were included in the Consolidated Statement of Income and related balances were reflected as Due to related party or Due from related party in the continuing operations and discontinued operations of the Consolidated Balance Sheet, as applicable. Other balances between the Company and Merck were considered to be effectively settled in the Consolidated Financial Statements at the time the transactions were recorded. See Note 19 for additional details. As the separate legal entities that made up the Company’s business were not historically held by a single legal entity, Net investment from Merck & Co., Inc. was shown in lieu of stockholders’ equity in these Consolidated Financial Statements. Net investment from Merck & Co., Inc. represented Merck’s interest in the recorded assets of the Company and the cumulative investment by Merck in the Company through the date of Separation, inclusive of operating results. Income tax expense and tax balances in the Consolidated Financial Statements were calculated on a separate tax return basis. The Company’s operations are included in the tax returns of certain Organon Entities, Transferred Entities or the respective Merck entities of which the Company’s business was a part. As of Separation Date Certain assets and liabilities, including accounts receivables, inventories and trade payables included on the Consolidated Balance Sheet prior to the Separation, have been retained by Merck post-Separation and therefore were transferred to Merck through Net investment from Merck & Co., Inc. in the Company’s Consolidated Financial Statements. Additionally, certain amounts previously included in Due to related party or Due from related party are reflected in accounts receivable and trade accounts payable as of December 31, 2021. As part of the Separation, Net investment from Merck & Co., Inc. was reclassified to Common Stock and Accumulated Deficit . In connection with the Separation, additional pension assets and obligations were transferred to Organon through Net investment from Merck & Co., Inc. , and the Company recorded these in the Consolidated Balance Sheet. See Note 14 for details. Additionally, stock-based awards were converted in accordance with the Employee Matters Agreement. See Note 13 for details. During the second quarter of 2021, an aggregate of $9.5 billion of debt was issued in connection with the Separation. (see Note 11 for additional details). The Company distributed $9.0 billion of the $9.5 billion proceeds to Merck in accordance with the terms of the Separation. Periods Post Separation Following the Separation, certain functions continue to be provided by Merck under the Transition Services Agreement or are being performed using the Company’s own resources or third-party service providers. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for Merck or its applicable affiliate, and Merck manufactures certain products for the Company or its applicable affiliate. The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company. Property, plant and equipment reflected in the Consolidated Balance Sheet is primarily attributable to the six manufacturing facilities the Company operates and certain information technology assets. In June 2021, the Company established a balance sheet risk management and a net investment hedging program to mitigate against volatility of changes in foreign exchange rates. As a standalone entity, the Company files tax returns on its own behalf, and tax balances and effective income tax rate may differ from the amounts reported in the historical periods. As of June 2, 2021 and in connection with the Separation, the Company adjusted its deferred tax balances and computed its related tax provision to reflect operations as a standalone entity. All intercompany transactions and accounts within Organon have been eliminated. Certain amounts presented in the prior period have been reclassified to conform to the current period presentation. During 2021, the Company recorded an out-of-period adjustment of approximately $145 million to establish a prepaid tax asset with an offsetting increase to Net Investment from Merck & Co., Inc . related to the period as of December 31, 2020. The adjustment did not have any impact on the Company's Consolidated Statement of Income or Consolidated Statement of Cash Flows. The Company concluded that the adjustment was not material to the Consolidated Financial Statements for either the current period or prior periods.
Reclassifications	Certain amounts presented in the prior period have been reclassified to conform to the current period presentation. During 2021, the Company recorded an out-of-period adjustment of approximately $145 million to establish a prepaid tax asset with an offsetting increase to Net Investment from Merck & Co., Inc . related to the period as of December 31, 2020. The adjustment did not have any impact on the Company's Consolidated Statement of Income or Consolidated Statement of Cash Flows. The Company concluded that the adjustment was not material to the Consolidated Financial Statements for either the current period or prior periods.
Revenue	Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. The Company acts as the principal in its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts have a single performance obligation — the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation. Revenues from sales of products, including tenders, are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. In the United States, sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, revenues are recorded net of time value of money discounts if collection of accounts receivable is expected to be in excess of one year. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The Company estimates the provision for chargebacks based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector, (Managed Care), and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history to estimate the expected provision. The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $2.0 billion in 2021, $1.8 billion in 2020, and $1.9 billion in 2019. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates in the United States included in Accounts receivable and Accrued and other current liabilities were $54 million and $275 million, respectively, at December 31, 2021 and $41 million and $302 million, respectively, at December 31, 2020. Outside of the United States, variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale. At December 31, 2021 and 2020, the accrued balances related to the provision for rebates and discounts included in other current liabilities were approximately $90 million and $115 million, respectively. The Company maintains a returns policy that allows its U.S. customers to return product within a specified period prior to and subsequent to the expiration date (generally, three The Company’s payment terms for U.S. customers are typically 36 days from receipt of invoice. Outside of the United States, payment terms are typically 30 days to 90 days, although certain markets have longer payment terms. See Note 18 for disaggregated revenue disclosures.
Cash Equivalents	Cash equivalents are comprised of certain highly liquid investments with original maturities of three months or less.
Inventories	Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method.
Value Added Tax	The Company’s purchases, sales and intercompany transfers of goods are subject to value added tax (VAT) and VAT receivables are recognized for amounts that represent credits against future VAT obligations. VAT receivables included in Other current asset s were $115 million and $315 million as of December 31, 2021 and 2020, respectively. VAT payables included in Accrued and other current liabilities were $9 million and $38 million as of December 31, 2021 and 2020, respectively. The related expense is included in the Company's operating expenses.
Depreciation	Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. The estimated useful lives primarily range from 25 to 40 years for buildings, and from 3 to 15 years for machinery, equipment and office furnishings. Depreciation expense was $92 million in 2021, $56 million in 2020, and $49 million in 2019. Repairs and maintenance costs are expensed as incurred as they do not extend the economic life of an asset.
Advertising and Promotion Cost	Advertising and promotion costs are expensed as incurred and included in Selling, general and administrative expenses.
Goodwill	Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is evaluated for impairment as of October 1 each year, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that fair value is less than carrying value. If the Company concludes it is more likely than not that fair value is less than carrying value, a quantitative fair value test is performed. If carrying value is greater than fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill). The Company completed the annual goodwill impairment test as of October 1, 2021 and concluded that no impairment to goodwill was necessary as the fair value of the reporting unit was significantly in excess of the carrying value.
Acquired Intangibles	Acquired intangibles include products and product rights and licenses, which are initially recorded at fair value, assigned an estimated useful life, and amortized on a straight-line basis over their estimated useful lives. The Company's intangibles also include the products and product rights intangible assets attributed to Organon from Merck. The intangible assets attributable to the Company’s operations have been reflected in the consolidated financial statements based on Merck’s historical cost. Licenses include milestone payments made to collaborative partners upon or subsequent to regulatory approval. The estimated useful lives of acquired intangibles range from 5 to 15 years (see Note 10). The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.
Acquired In-Process Research and Development	IPR&D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, Organon will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&D for impairment as of October 1 each year, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results. There were no IPR&D intangible assets as of December 31, 2021 or December 31, 2020.
Research and Development	Research and development costs are expensed as incurred. Research and development costs also include upfront and milestone payments related to asset acquisitions, licensing or collaborative arrangements involving clinical development programs that have not yet received regulatory approval.
Foreign Currency Translation	The net assets of international operations where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in Accumulated other comprehensive loss and reflected as a separate component of equity. For those operations that operate in highly inflationary economies and for those operations where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Other (income) expense, net.
Stock-Based Compensation	Prior to the Separation, certain of the Company’s employees historically participated in Merck’s share-based compensation plans. Share-based compensation expense was either allocated to the Company based on a proportionate cost allocation method or recorded based on specific identification. Effective June 3, 2021, Organon established the 2021 Incentive Stock Plan (the "Plan"). A total of 35 million shares of Common Stock are authorized under the Plan. The plan provides for the grant of various types of awards, including restricted stock unit awards, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. Accordingly, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants. The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change (see Note 13).In the second half of 2021, the Company granted stock option awards, performance share units and restricted share units under the 2021 Incentive Stock Plan. Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. Generally, stock options have a contractual term of ten years and vest one-third each year over a three-year period, subject to limited exceptions. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. RSU awards generally vest one-third each year over a three-year period. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company’s stock price. The terms of the Company's PSU awards allow the recipients of such awards to earn a variable number of shares based on total shareholder return of the Company relative to an index of peer companies ("relative TSR") specified in the awards. For PSUs with a market-based relative TSR goal, stock-based compensation expense is recognized based on the estimated fair value of the award at the grant date regardless of the actual number of shares earned. PSU awards generally vest after three years. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards.
Pension and Other Postretirement Benefit Plans	Prior to the Separation, the defined benefit plans in which the Company participated related primarily to plans sponsored by Merck and for which other businesses of Merck also participate (Shared Plans). The Company accounted for the Shared Plans as multiemployer plans and therefore the related assets and liabilities were not reflected in the Consolidated Balance Sheet. For such periods prior to Separation, the Consolidated Statement of Income reflects a proportional allocation of net periodic benefit cost for the Shared Plans associated with the Company. For certain defined benefit plans attributable to the Organon Entities, the over funded or underfunded status of the plan was recognized as an asset or liability on the combined balance sheet. The Company's participation in the defined pension and postretirement benefit plans sponsored by Merck concluded upon the completion of the Separation on June 2, 2021. At Separation, Organon became the plan sponsor for certain non-U.S. defined benefit pension plans (see Note 14).
Restructuring Costs	Costs associated with exit or disposal activities are recognized in the period in which they are incurred. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. When accruing these costs, the Company recognizes the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range.
Contingencies and Legal Defense Costs	The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.
Taxes on Income	Prior to the Separation, income tax expense and deferred tax balances were calculated on a separate tax return basis. The Company’s operations were included in the tax returns of certain Organon Entities, Transferring Entities or the respective Merck entities of which the Company’s business was a part. Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company establishes valuation allowances for its deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of Taxes on Income in the Consolidated Statement of Income. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company and Merck entered into the Tax Matters Agreement in connection with the Separation (See Note 19).
Leases	The Company has operating leases primarily for real estate. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if the Company controls the use of that asset. Embedded leases are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Real estate leases for facilities have a weighted average remaining lease term of 6.0 years and include one lease with an option to extend for 1 year. The Company has made an accounting policy election not to record short-term leases (leases with an initial term of 12 months or less) on the balance sheet. Lease expense associated with short term leases was not material for all periods presented. Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since most of the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments. On a quarterly basis, an updated incremental borrowing rate is determined based on the weighted average remaining lease term of each asset class and the Company's pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. The Company includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed) (See Note 11).
Use of Estimates	The presentation of these Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported. Estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, amounts recorded for contingencies, environmental liabilities, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill), investments, and taxes on income. Additionally estimates are used in acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. For periods prior to Separation, estimates were used in determining the allocation of costs and expenses from Merck, and were used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, valuation of goodwill and intangibles, amounts recorded for contingencies, environmental liabilities and other reserves, pension and share-based compensation assumptions, restructuring costs, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates. The COVID-19 pandemic continued to negatively affect the Company's results during 2021. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic at December 31, 2021 and through the date of this report.
Net Investment from Merck & Co., Inc	Net investment from Merc k & Co., Inc. represented Merck’s interest in the recorded assets of the Company and the cumulative investment by Merck in the Company through the date of Separation, inclusive of operating results and the net effect of the transactions with and allocations from Merck. See Notes 2 and 19 for additional information.
Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted	Recently Adopted Accounting Standards In January 2020, the Financial Accounting Standards Board ("FASB") issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company’s Consolidated Financial Statements upon adoption. In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities, clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination, and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company’s Consolidated Financial Statements upon adoption. Recently Issued Accounting Standards Not Yet Adopted In November 2021, the FASB issued new guidance requiring disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model. The guidance increases transparency about the types of transactions, the accounting for the transactions, and the effect of the transactions to the Company’s financial statements. The guidance is effective for the annual periods beginning in 2022 and can be applied on a prospective or retrospective basis. The Company is currently evaluating the impact of adoption on its Consolidated Financial Statements. In October 2021, the FASB issued guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance is effective for the Company on January 1, 2023 and its amendments applied prospectively to business combinations occurring on or after the effective date of the guidance. Early adoption is permitted, including adoption in an interim period and subject to different transition requirements. T he Company is currently evaluating the impact of adoption on its Consolidated Financial Statements. In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its Consolidated Financial Statements.

Samsung Collaboration (Tables)

Samsung Collaboration (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Collaborative Arrangement and Arrangement Other than Collaborative	Summarized information related to this collaboration is as follows: ($ in millions) 2021 2020 2019 Sales $ 424 $ 330 $ 252 Cost of sales 248 208 152 Selling, general and administrative 83 87 91 ($ in millions) December 31, 2021 December 31, 2020 Receivables from Samsung included in Other current assets $ 15 $ 52 Payables to Samsung included in Trade accounts payable 21 13

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
(Gain) Loss Derivative Instruments	Accordingly, the Consolidated Statement of Income includes the impact of Merck’s derivative financial instruments prior to the Separation that is deemed to be associated with the Company’s operations and has been allocated to the Company utilizing a proportional allocation method: ($ in millions) 2021 2020 2019 Allocated net (gains) loss in Sales $ 56 $ 3 $ (58) Net (gains) loss in Other (income) expense, net (1) 32 48 3 Foreign exchange (gains) loss in Other (income) expense, net (1) (28) (4) 70 (1) Includes net gains and losses and foreign exchange gains and losses allocated for the period prior to the Separation, as well as actual net gains and losses and foreign exchange gains and losses post-Separation.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consisted of: ($ in millions) December 31, 2021 December 31, 2020 Finished goods $ 377 $ 351 Raw materials 95 35 Work in process 490 595 Supplies 40 60 Total (approximates current cost) $ 1,002 $ 1,041 Decrease to LIFO costs (11) (1) $ 991 $ 1,040 Recognized as: Inventories $ 915 $ 913 Other assets 76 127
Schedule of Inventory, Noncurrent	Inventories consisted of: ($ in millions) December 31, 2021 December 31, 2020 Finished goods $ 377 $ 351 Raw materials 95 35 Work in process 490 595 Supplies 40 60 Total (approximates current cost) $ 1,002 $ 1,041 Decrease to LIFO costs (11) (1) $ 991 $ 1,040 Recognized as: Inventories $ 915 $ 913 Other assets 76 127

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	($ in millions) December 31, 2021 December 31, 2020 Land $ 14 $ 14 Building 667 647 Machinery, equipment and office furnishings 917 787 Construction in progress 257 356 Less: accumulated depreciation (882) (820) Property, Plant and Equipment, net $ 973 $ 984

Other Intangibles (Tables)

Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Other Intangibles	Other intangibles as of December 31 consists of: 2021 2020 ($ in millions) Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Products and product rights $ 24,195 $ 23,654 $ 541 $ 24,159 $ 23,787 $ 372 Licenses 201 91 110 201 70 131 $ 24,396 $ 23,745 $ 651 $ 24,360 $ 23,857 $ 503

Long-Term Debt and Leases (Tabl

Long-Term Debt and Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The following is a summary of Organon's total debt as described above: ($ in millions) December 31, 2021 Term Loan B Facility: LIBOR plus 300 bps term loan due 2028 $ 2,893 LIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million) 843 4.125% secured notes due 2028 2,100 2.875% euro-denominated secured notes due 2028 (€1.25 billion) 1,412 5.125% notes due 2031 2,000 Other borrowings 10 Other (discounts and debt issuance costs) (124) Total principal long-term debt $ 9,134 Less: Current portion of long-term debt 9 Total Long-term debt, net of current portion $ 9,125
Schedule of Maturities of Long-term Debt	The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows: ($ in millions) 2022 $ 9 2023 9 2024 9 2025 37 2026 43 Thereafter 9,151
Supplemental Balance Sheet	Supplemental balance sheet information related to operating leases is as follows: ($ in millions) December 31, 2021 December 31, 2020 Assets Other Assets $ 230 $ 31 Liabilities Accrued and other current liabilities 46 8 Other Noncurrent Liabilities 184 23 $ 230 $ 31 Weighted-average remaining lease term (years) 5.8 4.0 Weighted-average discount rate 3.3% 1.9%
Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of December 31, 2021 are as follows: 2022 $ 53 2023 52 2024 46 2025 40 2026 15 Thereafter 46 Total lease payments $ 252 Less: Imputed interest 22 $ 230

Stock-based Compensation Plans

Stock-based Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement, Expensed and Capitalized, Amount	Stock-based compensation expense incurred by the Company was as follows: ($ in millions) 2021 2020 2019 Stock-based compensation expense recognized in: Cost of sales $ 11 $ 17 $ 16 Selling, general and administrative 36 19 21 Research and Development 12 4 4 $ 59 $ 40 $ 41 Income tax benefits 12 8 9
Schedule of Stock Option Valuation Assumptions	The weighted average fair value of options was determined using the following assumptions: Year Ended December 31, 2021 Expected dividend yield 3.22 % Risk-free interest rate 0.92 % Expected volatility 45.80 % Expected term (years) 5.89
Share-based Payment Arrangement, Performance Shares, Activity	A summary of the transactions under the 2021 Incentive Stock Plan as of December 31, 2021 follows: Stock Options Restricted Share Units Performance Share Units (shares in thousands) Shares Weighted average exercise price Weighted average grant date fair value Shares Weighted average grant date fair value Shares Weighted average grant date fair value Outstanding as of June 2, 2021 4,097 $ 34.30 $ 8.55 3,311 $ 36.77 — $ — Granted 379 $ 35.38 $ 11.20 88 $ 34.72 120 $ 51.63 Vested/Exercised — $ — $ — (52) $ 38.46 — $ — Forfeited/Cancelled (82) $ 36.52 $ 9.05 (67) $ 36.55 — $ — Outstanding as of December 31, 2021 4,394 $ 34.35 $ 8.63 3,280 $ 36.69 120 $ 51.63
Share-based Payment Arrangement, Activity	The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable at December 31, 2021: Equity Awards Vested and Expected to Vest Equity Awards That are Exercisable (shares in thousands; aggregate intrinsic value in millions) Awards Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Term Awards Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Term Stock Options 4,134 $ 34.35 $ 2 8.02 1,454 $ 30.66 $ 2 5.65 Restricted Share Units 3,051 — 100 1.99 — — — — Performance Share Units 102 — 4 2.63 — — — —

Pension and Other Postretirem_2

Pension and Other Postretirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Schedule of Net Benefit Costs	The net periodic benefit cost for pension plans consisted of the following components: ($ in millions) 2021 2020 2019 Service cost $ 17 $ 4 $ 3 Interest cost 2 1 1 Expected return on plan assets (3) (1) (1) Net loss amortization 2 — — Net periodic benefit cost $ 18 $ 4 $ 3
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan	Summarized information about changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows: ($ in millions) 2021 2020 Fair value of plan assets January 1 $ 40 $ 28 Actual return on plan assets 6 — Company contributions 19 4 Effects of exchange rate changes (6) 3 Benefits paid 2 (1) Other — 7 Net transfer of plan assets from Merck affiliates 56 (1) Fair value of plan assets December 31 $ 117 $ 40 Benefit obligation January 1 $ 76 $ 54 Service cost 17 4 Interest cost 2 1 Actuarial losses (17) 4 Benefits paid 2 (1) Effects of exchange rate changes (10) 6 Other — 6 Net transfer of benefit obligations from Merck affiliates 119 2 Benefit obligation December 31 $ 189 $ 76 Funded status December 31 $ (72) $ (36) Recognized as: Other assets $ 1 $ — Accrued and other current liabilities (1) — Other Noncurrent liabilities (72) (36)
Schedule of Allocation of Plan Assets	The fair values of the Company’s pension plan assets at December 31 by asset category are as follows: Fair Value Measurements Using Fair Value Measurements Using Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 2021 2020 Cash and cash equivalents $ 3 $ — $ — $ 3 $ — $ — $ — $ — Investment funds Developed markets equities 28 3 — 31 — — — — Government and agency obligations 21 1 — 22 — — — — Emerging markets equities 5 — — 5 — — — — Other 3 1 — 4 — — — — Equity income securities Developed markets equities 1 — — 1 — — — — Fixed income securities Government and agency obligations — 3 — 3 — 5 — 5 Corporate Obligations — 2 — 2 — — — — Other investments Insurance contracts — 33 — 33 — 34 — 34 Other 12 1 — 13 — 1 — 1 Plan assets at fair value $ 73 $ 44 $ — $ 117 $ — $ 40 $ — $ 40
Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)	Net loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. ($ in millions) 2021 2020 2019 Net gain (loss) arising during the period $ 4 $ 6 $ (5) Net loss amortization included in benefit cost 2 — —
Defined Benefit Plan, Assumptions	The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining pension plan information are as follows: ($ in millions) 2021 2020 2019 Net periodic benefit cost Discount rate 1.48 % 3.91 % 4.14 % Expected rate of return on plan assets 4.50 % 2.62 % 3.08 % Salary growth rate 3.18 % 3.63 % 3.36 % Benefit obligation Discount rate 1.49 % 1.52 % 1.63 % Salary growth rate 2.75 % 3.63 % 3.33 %
ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock	Information related to the funded status of materially significant pension plans at December 31 is as follows: ($ in millions) 2021 2020 Pension plans with a projected benefit obligation in excess of plan assets Projected benefit obligation $ 176 $ 76 Fair value of plan assets 104 38 Pension plans with an accumulated benefit obligation in excess of plan assets Accumulated benefit obligation $ 154 $ 54 Fair value of plan assets 97 38

Other (Income) Expense, Net (Ta

Other (Income) Expense, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
Schedule of Other Operating and Nonoperating Income (Expense)	Other (income) expense, net, consisted of: ($ in millions) 2021 2020 2019 Exchange (gains) losses $ 4 $ 44 $ 73 Interest expense 258 — — Other, net 17 (9) (7) $ 279 $ 35 $ 66

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation between the effective tax rate and the U.S. statutory rate is as follows: 2021 2020 2019 ($ in millions) Amount Tax Rate Amount Tax Rate Amount Tax Rate U.S. statutory rate applied to income before taxes $ 321 21.0 % $ 578 21.0 % $ 776 21.0 % Differential arising from: Foreign earnings (43) (2.8) (93) (3.4) (143) (3.9) Tax settlements (32) (2.1) — — (264) (7.1) Amortization of intangible assets (75) (4.9) 12 0.4 22 0.6 State taxes (3) (0.2) — — 5 0.1 Global Intangible Low-Taxed Income 17 1.1 — Other (7) (0.4) (1) — (6) (0.1) $ 178 11.7 % $ 496 18.0 % $ 390 10.6 %
Schedule of Income before Income Tax, Domestic and Foreign	Income before taxes consisted of: ($ in millions) 2021 2020 2019 Domestic $ (96) $ 532 $ 564 Foreign 1,625 2,220 3,132 $ 1,529 $ 2,752 $ 3,696
Schedule of Deferred Tax Assets and Liabilities	Deferred income taxes at December 31 consisted of: 2021 2020 ($ in millions) Assets Liabilities Assets Liabilities Product intangibles and licenses $ 105 $ — $ 24 $ — Inventory related 15 — — 18 Reserves and allowances 40 — 39 — Accrued expenses 23 — — — Accelerated depreciation — 15 — — Unremitted foreign earnings — 2 — 78 Right of use asset 51 — — — Lease liability — 51 — — Interest expense limitation carryforward 23 — — — Compensation related 23 — — — Unrecognized tax benefits — — 18 — Hedging — 36 — — Net operating losses and other tax credit carryforwards 103 — 70 — Other 24 — 36 — Subtotal $ 407 $ 104 $ 187 $ 96 Valuation allowance (35) — (69) — Total deferred taxes $ 372 $ 104 $ 118 $ 96 Net deferred income taxes $ 268 $ 22 Recognized as: Other Assets $ 272 $ 150 Deferred Income Taxes $ 4 $ 128
Schedule of Unrecognized Tax Benefits Roll Forward	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: ($ in millions) 2021 2020 2019 Balance January 1 $ 219 $ 213 $ 619 Additions related to current year tax positions 23 15 12 Additions related to prior year tax positions 18 23 4 Reductions for tax positions of prior years (1) (49) (3) (274) Spinoff related adjustments (2) (108) — — Settlements (15) (19) (140) Lapse of statute of limitations (10) (10) (8) Balance December 31 $ 78 $ 219 $ 213 (1) Amounts in 2019 reflect the settlement with the IRS discussed below. (2) Unrecognized tax benefits were reduced by $108 million in 2021 related to positions taken prior to the spinoff for which Merck, as the Company’s former Parent, is the primary obligor and is responsible for settlement and payment of any resulting tax obligation.
Schedule of Components of Income Tax Expense (Benefit)	Taxes on income consisted of: ($ in millions) 2021 2020 2019 Current provision Federal $ 41 $ 91 $ (126) Foreign 435 435 549 State (10) 2 (45) $ 466 $ 528 $ 378 Deferred provision Federal $ (64) $ 11 $ 3 Foreign (220) (44) (10) State (4) 1 19 $ (288) $ (32) $ 12 $ 178 $ 496 $ 390

Other Comprehensive Income (L_2

Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Changes of AOCI by Component	Changes in Accumulated other comprehensive loss by component are as follows: ($ in millions) Employee Cumulative Accumulated Other Balance at January 1, 2019, net of taxes $ (294) $ (614) $ (908) Other comprehensive income (loss), pretax (68) 54 (14) Tax 8 — 8 Other comprehensive income (loss), net of taxes (60) 54 (6) Balance at December 31, 2019, net of taxes $ (354) $ (560) $ (914) Other comprehensive income (loss), pretax (172) (30) (202) Tax 29 — 29 Other comprehensive income (loss), net of taxes (143) (30) (173) Net Transfer of benefit plans to Merck affiliates $ 465 $ — $ 465 Balance at December 31, 2020, net of taxes $ (32) $ (590) $ (622) Other comprehensive income (loss), pretax 21 90 111 Tax (13) — (13) Other comprehensive income (loss), net of taxes 8 90 98 Net transfer of benefit plans to Merck affiliates 11 — 11 Balance at December 31, 2021, net of taxes $ (13) $ (500) $ (513)

Product and Geographic Inform_2

Product and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Sales of Company's products	of the Company’s products were as follows: 2021 2020 2019 ($ in millions) U.S. Int’l Total U.S. Int’l Total U.S. Int’l Total Women’s Health Nexplanon/Implanon NXT $ 532 $ 237 $ 769 $ 488 $ 192 $ 680 $ 568 $ 219 $ 787 Follistim AQ 110 127 237 84 108 193 103 138 241 NuvaRing 85 106 191 111 126 236 744 134 879 ganirelix acetate injection 22 88 111 11 69 81 25 86 112 Cerazette — 70 70 — 67 67 — 71 71 Other Women's Health (1) 96 139 234 165 133 298 18 156 173 Biosimilars Renflexis 164 21 186 123 12 135 95 1 96 Ontruzant 34 92 126 3 113 115 — 83 83 Brenzys — 63 63 — 74 74 — 72 72 Other Biosimilars (1) — 49 49 — 6 6 — — — Established Brands Cardiovascular Zetia 10 368 378 (1) 483 482 14 575 590 Vytorin 11 153 164 12 170 182 16 268 285 Atozet — 458 458 — 453 453 — 391 391 Rosuzet — 68 68 — 130 130 — 120 120 Cozaar/Hyzaar 12 345 357 21 365 386 25 417 442 Zocor 4 61 65 3 75 77 6 107 112 Other Cardiovascular (1) — 126 126 — 162 162 — 134 134 Respiratory Singulair 15 398 413 18 444 462 30 669 698 Nasonex 4 201 206 12 206 218 9 284 293 Dulera 154 36 190 188 34 222 189 29 217 Clarinex 6 106 111 7 123 130 8 133 142 Asmanex 57 7 63 76 8 83 84 9 94 Other Respiratory (1) — 26 26 3 32 35 1 25 25 Non-Opioid Pain, Bone and Dermatology Arcoxia — 244 244 — 258 258 — 288 288 Fosamax 4 172 175 4 176 180 9 188 197 Diprospan — 125 125 — 118 118 — 102 102 Diprosone 1 86 87 1 82 83 1 83 84 Other Non-Opioid Pain, Bone and Dermatology (1) 15 183 199 9 186 195 14 199 214 Other Proscar 1 116 117 2 174 176 2 202 203 Propecia 9 127 136 10 119 129 11 120 131 Sinemet — 71 71 (1) 78 77 1 78 79 Remeron 3 62 66 2 61 64 3 79 82 Other (1) 37 185 223 53 185 238 62 176 238 Other (2) (3) 205 200 4 102 107 (17) 120 102 Total Revenue $ 1,383 $ 4,921 $ 6,304 $ 1,408 $ 5,124 $ 6,532 $ 2,021 $ 5,756 $ 7,777 U.S. plus international may not equal total due to rounding . (1) Includes sales of products not listed separately. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health. (2) Includes manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.
Consolidated revenues by geographic area	Combined sales by geographic area where derived are as follows: ($ in millions) 2021 2020 2019 Europe and Canada $ 1,741 $ 1,726 $ 1,893 United States 1,383 1,408 2,021 Asia Pacific and Japan 1,173 1,535 1,789 China 933 873 1,027 Latin America, Middle East, Russia and Africa 841 857 923 Other (1) 233 133 124 $ 6,304 $ 6,532 $ 7,777 (1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.

Third Party Arrangements and _2

Third Party Arrangements and Related Party Disclosures (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The allocations reflected in the Consolidated Statement of Income for continuing operations are as follows: ($ in millions) 2021 (1) 2020 2019 Cost of sales $ 69 $ 452 $ 520 Selling, general and administrative 134 658 725 Research and development 35 152 190 $ 238 $ 1,262 $ 1,435 (1) Includes costs through the Separation Date. The following transactions represent activity between Organon Entities and Transferred Entities with other Merck affiliates prior to the Separation: ($ in millions) 2021 2020 2019 Included in continuing operations Supply sales to Merck affiliates $ 143 $ 57 $ — Purchases from Merck affiliates 65 657 — Cost reimbursements and fees from Merck affiliates 1 — — Included in discontinued operations Supply sales to Merck affiliates $ 12 $ 542 $ 501 Purchases from Merck affiliates 53 382 1,087 Cost reimbursements and fees (to) from Merck affiliates $ — $ 22 $ 19 Interest expense, net on loans and advances with Merck affiliates $ — $ 2 $ 3 The Company had the following balances with Merck affiliates: ($ in millions) December 31, 2020 Included in continuing operations Short term borrowings, net $ 1,512 Trade payables (receivables), net (173) Due to related party $ 1,339 Included in discontinued operations Short term loans receivables, net $ 247 Short term notes payable, net (25) Trade payables, net (33) Due from related party $ 189 Net transfers to Merck & Co., Inc. were as follows: ($ in millions) 2021 (1) 2020 2019 Cash pooling and general financing activities $ 168 $ 5,216 $ 5,310 Cost allocations, excluding non-cash stock-based compensation (209) (1,222) (1,394) Taxes deemed settled with Merck (259) (409) (1,039) Allocated derivative and hedging (losses) gains (88) (51) 55 Net transfers (from) to Merck & Co., Inc. as reflected in the Consolidated Statement of Cash Flows for Continuing Operations (2) $ (388) $ 3,534 $ 2,932 Net transfers to (from) Merck included in Net Cash Provided by (Used in) Discontinued Operations 597 (194) (355) Total net transfers to Merck as included in the Consolidated Statement of Cash Flows $ 209 $ 3,340 $ 2,577 Stock-based compensation expense (includes $3 and $7 of discontinued operations for 2021 and 2020, respectively) (32) (54) (52) Net assets (distributed to) contributed by Merck affiliates (778) 250 — Recognition of amounts in Accumulated other comprehensive loss related to employee benefit plan transfers to Merck affiliates 13 465 — Net transfers (from) to Merck & Co., Inc. as reflected in the Consolidated Statement of Equity $ (588) $ 4,001 $ 2,525 (1) The amounts for the year ended December 31, 2021 represent activity through the date of the Separation. (2) Net transfers (from) to Merck & Co., Inc. as reflected in the Consolidated Statement of Cash Flows for Continuing Operations for the year ended December 31, 2021 include Separation adjustments of $52 million, identified after the date of the Separation. Refer to Note 2 for further details.

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	The components of Income (loss) from discontinued operations, net of tax for the Merck Retained Products business are as follows: ($ in millions) 2021 2020 2019 Sales $ 93 $ 1,564 $ 1,753 Costs, Expenses and Other Cost of Sales 65 1,228 1,347 Selling, general and administrative 15 310 479 Research and development 4 94 112 Restructuring costs — 10 23 Other (income) expense, net 4 (6) (67) Income (loss) from discontinued operations before taxes $ 5 $ (72) $ (141) Taxes on income 5 24 (53) Loss from discontinued operations, net of taxes $ — $ (96) $ (88) The components of assets and liabilities of discontinued operations that are stated separately as of December 31, 2020 in the Consolidated Balance Sheets are comprised of the following items: ($ in millions) December 31, 2020 Assets Cash and cash equivalents $ 58 Accounts receivable 322 Inventories 58 Due from related party 189 Other current assets 47 Total current assets of discontinued operations 674 Property, Plant and Equipment, net 14 Other Noncurrent Assets 77 Total Noncurrent Assets of Discontinued Operations 91 Total Assets of Discontinued Operations $ 765 Liabilities Trade accounts payable $ 35 Accrued and other current liabilities 93 Total current liabilities of discontinued operations 128 Deferred Income Taxes — Other Noncurrent Liabilities 83 Total Noncurrent Liabilities of Discontinued Operations 83 Total Liabilities of Discontinued Operations $ 211

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The calculation of basic and diluted earnings per common share for the year ended December 31, 2021, 2020 and 2019 was as follows: ($ in millions and shares in thousands, except per share amounts) 2021 2020 2019 Net income attributable to Organon: Income from continuing operations $ 1,351 $ 2,256 $ 3,306 Income from discontinued operations — (96) (88) Net income attributable to Organon $ 1,351 $ 2,160 $ 3,218 Basic weighted average number of shares outstanding 253,538 253,516 253,516 Stock awards and equity units (share equivalent) 655 — — Diluted weighted average common shares outstanding 254,193 253,516 253,516 Earnings (Loss) Per Share Attributable to Organon common stockholders - Basic Income from continuing operations $ 5.33 $ 8.90 $ 13.04 Loss from discontinued operations — (0.38) (0.35) Basic earnings per common share attributable to Organon common stockholders $ 5.33 $ 8.52 $ 12.69 Earnings (Loss) Per Share Attributable to Organon common stockholders - Diluted Income from continuing operations 5.31 8.90 13.04 Loss from discontinued operations — (0.38) (0.35) Diluted earnings per common share attributable to Organon common stockholders $ 5.31 $ 8.52 $ 12.69

Background and Nature of Oper_2

Background and Nature of Operations (Details)	Dec. 31, 2021manufacturingFacility$ / shares	May 17, 2021$ / sharesshares
Class of Stock [Line Items]
Number of manufacturing facilities | manufacturingFacility	6
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Merck and Co., Inc.
Class of Stock [Line Items]
Common stock, par value (in dollars per share)		$ 0.50
Shares distributed to each shareholder | shares		0.1

Basis of Presentation (Details)

Basis of Presentation (Details) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Dec. 31, 2021USD ($)manufacturingFacility	Dec. 31, 2020USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from issuance of debt		$ 9,500
Dividend payments	$ 9,000	$ 9,000
Number of manufacturing facilities | manufacturingFacility			6
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net investment from Merck & Co., Inc.			$ 0	$ 6,108
Net transfers from Merck & Co., Inc., including Separation Adjustments			664
Accumulated deficit			(998)	0
Revision of Prior Period, Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Prepaid taxes			145
Net investment from Merck & Co., Inc.				$ 145
Net assets			65
Accumulated deficit			$ 65

Summary of Accounting Policie_2

Summary of Accounting Policies (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)lease	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jun. 03, 2021shares
Property, Plant and Equipment [Line Items]
Customer discounts	$ 2,000	$ 1,800	$ 1,900
Product return period and expiration	12 months
Value added tax receivable	$ 115	315
Value added tax payable	9	38
Depreciation	92	56	49
Advertising and promotion costs	236	198	$ 262
Acquired IPR&D	$ 0	$ 0
Weighted-average remaining lease term (years)	5 years 9 months 18 days	4 years
2021 Incentive Stock Plan
Property, Plant and Equipment [Line Items]
Number of shares authorized | shares				35,000,000
U.S.
Property, Plant and Equipment [Line Items]
Accrual for chargebacks reflected as direct reduction to accounts receivable	$ 54	$ 41
Accrual for rebates included in accrued and other current liabilities	$ 275	302
Payment terms	36 days
International
Property, Plant and Equipment [Line Items]
Accrual for rebates included in accrued and other current liabilities	$ 90	$ 115
Real Estate
Property, Plant and Equipment [Line Items]
Weighted-average remaining lease term (years)	6 years
Number of leases with options to renew | lease	1
Operating lease renewal term	1 year
Minimum
Property, Plant and Equipment [Line Items]
Product return period	3 months
Expected useful life	5 years
Minimum | International
Property, Plant and Equipment [Line Items]
Payment terms	30 days
Minimum | Building
Property, Plant and Equipment [Line Items]
Useful life	25 years
Minimum | Machinery, equipment and office furnishings
Property, Plant and Equipment [Line Items]
Useful life	3 years
Maximum
Property, Plant and Equipment [Line Items]
Product return period	6 months
Expected useful life	15 years
Maximum | International
Property, Plant and Equipment [Line Items]
Payment terms	90 days
Maximum | Building
Property, Plant and Equipment [Line Items]
Useful life	40 years
Maximum | Machinery, equipment and office furnishings
Property, Plant and Equipment [Line Items]
Useful life	15 years

Samsung Collaboration - Narrati

Samsung Collaboration - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Brazil
Disaggregation of Revenue [Line Items]
Gross profit sharing arrangement percentage	35.00%
Samsung Bioepis
Disaggregation of Revenue [Line Items]
Collaboration agreement period	10 years
Potential future regulatory milestone payments	$ 25
Samsung Bioepis | Brazil
Disaggregation of Revenue [Line Items]
Gross profit sharing arrangement percentage	65.00%

Samsung Collaboration - Summari

Samsung Collaboration - Summarization of Collaboration Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 6,304	$ 6,532	$ 7,777
Cost of sales	2,382	2,119	2,274
Selling, general and administrative	1,668	1,356	1,443
Receivables from Samsung included in Other current assets	1,382	1,038
Payables to Samsung included in Trade accounts payable	1,382	259
Samsung Bioepis
Disaggregation of Revenue [Line Items]
Revenues	424	330	252
Cost of sales	248	208	152
Selling, general and administrative	83	87	$ 91
Receivables from Samsung included in Other current assets	15	52
Payables to Samsung included in Trade accounts payable	$ 21	$ 13

Acquisitions and Licensing Ar_2

Acquisitions and Licensing Arrangements (Details) - USD ($) $ in Millions	1 Months Ended			12 Months Ended
	Dec. 31, 2021	Jul. 31, 2021	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Asset Acquisition [Line Items]
Research and development				$ 443	$ 210	$ 220
Forendo Pharma
Asset Acquisition [Line Items]
Acquisition payment	$ 75
Assumption of debt	10
Commercial milestone payments	600			600
Development and regulatory payments	270			270
Transaction consideration	$ 955
Research and development				79
Transaction costs				$ 5
Alydia Health
Asset Acquisition [Line Items]
Transaction consideration			$ 219
Sales-based contingent milestone			25
Intangible assets acquired			$ 247
Expected useful life			11 years
Other net liabilities			$ 7
Deferred tax liabilities			44
Compensation expense			23
Accelerated vesting of awards			$ 19
ObsEva | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Asset Acquisition [Line Items]
Commercial milestone payments		$ 385
Development and regulatory payments		90
Research and development		$ 25

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Restructuring costs	$ 3	$ 60	$ 78
Severance costs		30	70
Other restructuring costs		30	$ 8
Restructuring activities	$ 0	$ 17

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency transaction (gain) loss	$ 18	$ (5)	$ 0
Sales
Derivative Instruments, Gain (Loss) [Line Items]
Net (gains) loss on derivatives	56	3	(58)
Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Net (gains) loss on derivatives	32	48	3
Foreign currency transaction (gain) loss	$ (28)	$ (4)	$ 70

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) $ in Millions	3 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2021EUR (€)	Jun. 02, 2021EUR (€)	Apr. 30, 2021EUR (€)
Derivative Instruments, Gain (Loss) [Line Items]
Fair value hedge assets	$ 19
Fair value hedge liabilities	5
Accounts receivables factored	87
Foreign Exchange Forward
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	$ 2,100
Merck and Co., Inc.
Derivative Instruments, Gain (Loss) [Line Items]
Accounts receivables factored		$ 227
Senior Notes | Organon Finance 1 LLC
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of debt (in euros) | €					€ 1,250,000,000
Euro Denominated Term Loan B | Senior Notes
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of debt (in euros) | €				€ 750,000,000
Euro Denominated Term Loan B | Senior Notes | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of debt (in euros) | €			€ 750,000,000
2.875% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC
Derivative Instruments, Gain (Loss) [Line Items]
Stated interest rate					2.875%
2.875% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of debt (in euros) | €			€ 1,250,000,000
Stated interest rate	2.875%		2.875%
Euro Denominated Term Loan | Senior Notes
Derivative Instruments, Gain (Loss) [Line Items]
Gain on derivative	$ 162
Euro Denominated Term Loan | Senior Notes | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of debt (in euros) | €			€ 1,750,000,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Finished goods	$ 377	$ 351
Raw materials	95	35
Work in process	490	595
Supplies	40	60
Total (approximates current cost)	1,002	1,041
Decrease to LIFO costs	(11)	(1)
Inventory	991	1,040
Recognized as:
Inventories	915	913
Other assets	76	127
Inventories valued under LIFO	52	$ 48
Inventory [Line Items]
Purchase obligations	1,500
Purchase obligations in the next 12 months	349
Vendor Supply Contract
Inventory [Line Items]
Inventory impairment	$ 24

Property, Plant, and Equipmen_2

Property, Plant, and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation	$ (882)	$ (820)
Property, plant and equipment, net	973	984
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	14	14
Building
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	667	647
Machinery, equipment and office furnishings
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	917	787
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 257	$ 356

Other Intangibles - Other Intan

Other Intangibles - Other Intangibles (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 24,396	$ 24,360
Accumulated Amortization	23,745	23,857
Net	651	503
Products and product rights
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	24,195	24,159
Accumulated Amortization	23,654	23,787
Net	541	372
Licenses
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	201	201
Accumulated Amortization	91	70
Net	$ 110	$ 131

Other Intangibles - Narrative (

Other Intangibles - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Other intangibles, net	$ 651	$ 503
Impairment charges	7
Aggregate amortization expense	103	86	$ 284
2022	108
2023	107
2024	101
2025	99
2026	94
Products and product rights
Finite-Lived Intangible Assets [Line Items]
Other intangibles, net	541	372
Products and product rights | Nexplanon/Implanon NXT
Finite-Lived Intangible Assets [Line Items]
Other intangibles, net	296	354
Products and product rights | Jada System Device
Finite-Lived Intangible Assets [Line Items]
Other intangibles, net	247
Licenses
Finite-Lived Intangible Assets [Line Items]
Other intangibles, net	110	131
Licenses | Samsung Bioepis Collaboration
Finite-Lived Intangible Assets [Line Items]
Other intangibles, net	$ 87	$ 113

Long-Term Debt and Leases - Nar

Long-Term Debt and Leases - Narrative (Details)	Dec. 23, 2021USD ($)	Jun. 02, 2021USD ($)	Apr. 30, 2021USD ($)	Dec. 31, 2021USD ($)lease	Jun. 30, 2021USD ($)	Dec. 31, 2021USD ($)lease	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jun. 02, 2021EUR (€)	Apr. 30, 2021EUR (€)
Debt Instrument [Line Items]
Dividend payments			$ 9,000,000,000		$ 9,000,000,000
Debt issuance costs				$ 117,000,000		$ 117,000,000
Debt discounts				19,000,000		19,000,000
Other (discounts and debt issuance costs)				124,000,000		124,000,000
Fair value of long-term debt				9,400,000,000		9,400,000,000
Long-term debt				$ 9,134,000,000		9,134,000,000
Debt instrument interest payments						188,000,000
Repayments of long-term debt	$ 100,000,000					$ 112,000,000	$ 0	$ 0
Average maturity of long-term debt						7 years
Weighted average interest rate of debt				3.90%
Weighted-average remaining lease term (years)				5 years 9 months 18 days		5 years 9 months 18 days	4 years
Operating lease cost						$ 66,000,000	$ 40,000,000	45,000,000
Operating lease payments						41,000,000	5,000,000	6,000,000
Operating lease assets obtained in exchange for operating lease liability						$ 241,000,000	$ 23,000,000	$ 4,000,000
Number of leases not yet commenced | lease				2		2
Amount of operating lease not yet commenced				$ 7,400,000		$ 7,400,000
Real Estate
Debt Instrument [Line Items]
Weighted-average remaining lease term (years)				6 years		6 years
Number of leases with options to renew | lease				1		1
Operating lease renewal term				1 year		1 year
Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Face amount of debt | €										€ 1,250,000,000
Senior Notes | Term Loan B Facility
Debt Instrument [Line Items]
Face amount of debt		$ 3,000,000,000
Debt term		7 years
Interest payment terms		0.25%
Senior Notes | Term Loan B Facility | Adjusted LIBOR
Debt Instrument [Line Items]
Spread on variable rate		3.00%
Senior Notes | Term Loan B Facility | Adjusted LIBOR | Minimum
Debt Instrument [Line Items]
Spread on variable rate		0.50%
Senior Notes | Term Loan B Facility | Alternate Base Rate
Debt Instrument [Line Items]
Spread on variable rate		2.00%
Senior Notes | Term Loan B Facility | Adjusted EURIBOR
Debt Instrument [Line Items]
Spread on variable rate		3.00%
Senior Notes | Term Loan B Facility | Adjusted EURIBOR | Minimum
Debt Instrument [Line Items]
Spread on variable rate		0.00%
Senior Notes | 2.875% Senior Secured Notes Due 2028 | Organon Finance 1 LLC
Debt Instrument [Line Items]
Stated interest rate			2.875%							2.875%
Senior Notes | 4.125% Senior Secured Notes Due 2028 | Organon Finance 1 LLC
Debt Instrument [Line Items]
Face amount of debt			$ 2,100,000,000
Stated interest rate			4.125%	4.125%		4.125%				4.125%
Senior Notes | 5.125% Senior Unsecured Notes Due 2031 | Organon Finance 1 LLC
Debt Instrument [Line Items]
Face amount of debt			$ 2,000,000,000
Stated interest rate			5.125%	5.125%		5.125%				5.125%
Senior Notes | Euro Denominated Term Loan B
Debt Instrument [Line Items]
Face amount of debt | €									€ 750,000,000
Debt term		7 years
Revolving Credit Facility
Debt Instrument [Line Items]
Debt term		5 years
Borrowing capacity		$ 1,000,000,000
Unused capacity commitment fee percentage		0.50%
Step down on unused capacity commitment fee		0.375%
Line of credit				$ 0		$ 0
Revolving Credit Facility | Adjusted LIBOR
Debt Instrument [Line Items]
Spread on variable rate		2.00%
Revolving Credit Facility | Adjusted LIBOR | Minimum
Debt Instrument [Line Items]
Spread on variable rate		0.00%
Revolving Credit Facility | Alternate Base Rate
Debt Instrument [Line Items]
Spread on variable rate		1.00%
Revolving Credit Facility | Adjusted EURIBOR
Debt Instrument [Line Items]
Spread on variable rate		2.00%

Long-Term Debt and Leases - Sum

Long-Term Debt and Leases - Summary of Debt (Details)	12 Months Ended
	Dec. 31, 2021USD ($)	Jun. 02, 2021USD ($)	Jun. 02, 2021EUR (€)	Apr. 30, 2021USD ($)	Apr. 30, 2021EUR (€)	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Other (discounts and debt issuance costs)	$ (124,000,000)
Total principal long-term debt	9,134,000,000
Current portion of long-term debt	9,000,000					$ 0
Total Long-term debt, net of current portion	9,125,000,000					$ 0
Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Face amount of debt | €					€ 1,250,000,000
Other borrowings
Debt Instrument [Line Items]
Long-term debt	10,000,000
Term Loan B Facility | Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 2,893,000,000
Face amount of debt		$ 3,000,000,000
Term Loan B Facility | Senior Notes | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Spread on variable rate	3.00%
Euro Denominated Term Loan B | Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 843,000,000
Face amount of debt | €			€ 750,000,000
Euro Denominated Term Loan B | Senior Notes | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Spread on variable rate	3.00%
4.125% Senior Secured Notes Due 2028 | Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 2,100,000,000
4.125% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Stated interest rate	4.125%			4.125%	4.125%
Face amount of debt				$ 2,100,000,000
2.875% Senior Secured Notes Due 2028 | Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 1,412,000,000
2.875% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Stated interest rate				2.875%	2.875%
5.125% Senior Unsecured Notes Due 2031 | Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 2,000,000,000
5.125% Senior Unsecured Notes Due 2031 | Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Stated interest rate	5.125%			5.125%	5.125%
Face amount of debt				$ 2,000,000,000

Long-Term Debt and Leases - Sch

Long-Term Debt and Leases - Schedule of Debt Principal Payments (Details) $ in Millions	Dec. 31, 2021USD ($)
Debt Disclosure [Abstract]
2022	$ 9
2023	9
2024	9
2025	37
2026	43
Thereafter	$ 9,151

Long-Term Debt and Leases - Sup

Long-Term Debt and Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets
Other Assets	$ 230	$ 31
Liabilities
Accrued and other current liabilities	46	8
Other Noncurrent Liabilities	184	23
Present value of lease liabilities	$ 230	$ 31
Weighted-average remaining lease term (years)	5 years 9 months 18 days	4 years
Weighted-average discount rate	3.30%	1.90%
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other noncurrent liabilities	Other noncurrent liabilities
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued and other current liabilities	Accrued and other current liabilities

Long-Term Debt and Leases - Mat

Long-Term Debt and Leases - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
2022	$ 53
2023	52
2024	46
2025	40
2026	15
Thereafter	46
Total lease payments	252
Less: Imputed interest	22
Present value of lease liabilities	$ 230	$ 31

Contingencies (Details)

Contingencies (Details) $ in Millions	1 Months Ended	12 Months Ended
	Mar. 31, 2014case	Dec. 31, 2021USD ($)case	Dec. 31, 2018USD ($)	Dec. 31, 2020USD ($)
Loss Contingencies [Line Items]
Amount of legal defense reserves | $		$ 9		$ 35
Accrued liabilities for environmental matters | $		$ 24		$ 24
Term for paying off environmental liabilities		15 years
Fosamax
Loss Contingencies [Line Items]
Number of pending claims		3,470
Fosamax | Federal | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims		975
Number of claims dismissed	650
Number of claims on appeal	515
Fosamax | New Jersey State Court | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims		2,215
Fosamax | California State Court | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims		275
Fosamax | Other State Courts | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims		4
Propecia/ Proscar | U.S.
Loss Contingencies [Line Items]
Number of pending claims		3
Propecia/ Proscar | Outside the United States
Loss Contingencies [Line Items]
Number of pending claims		18
Number of pending class actions		2
Number of pending putative class actions		4
Propecia/ Proscar | New Jersey Coordinated Proceedings
Loss Contingencies [Line Items]
Amount awarded to other party | $			$ 4.3
Plaintiff participation percentage			95.00%
Plaintiff clawback participation rate percentage			100.00%
Nexplanon/Implanon NXT | Outside the United States
Loss Contingencies [Line Items]
Number of pending claims		20
Nexplanon | Outside the United States
Loss Contingencies [Line Items]
Number of pending claims		4
Implanon | Outside the United States
Loss Contingencies [Line Items]
Number of pending claims		16
Implanon | Northern District of Ohio
Loss Contingencies [Line Items]
Number of pending claims		2
Number of unfiled claims		56

Stock-based Compensation Plan_2

Stock-based Compensation Plans - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Jun. 03, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental stock-based compensation expense				$ 17
Options, grants (in shares)			379,000
Amount of unrecognized compensation costs		$ 109	$ 109	109	$ 109
Amount of unrecognized compensation costs period for recognition					2 years 29 days
Stock-based compensation expense recognized in:					$ 59	$ 40	$ 41
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized in:					11	17	16
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized in:					36	19	21
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized in:					12	$ 4	$ 4
2021 Incentive Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	35,000,000
Vested option awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental stock-based compensation expense				4
Unrecognized incremental stock-based compensation expense		$ 9.7	$ 9.7	$ 9.7	$ 9.7
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental options remaining vesting period				2 years 7 months 28 days
Award vesting rights percentage					33.30%
Converted from Merck, stock options, shares	4,100,000
Converted from Merck, stock options, average price (in usd per share)	$ 8.55
Stock appreciation rights and options | 2021 Incentive Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration period		10 years
Award vesting rights		three-year
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights percentage					33.30%
Conversion of shares awards issued	3,300,000
Converted from Merck, restricted share units average price (in usd per share)	$ 36.77
Restricted Stock Units (RSUs) | 2021 Incentive Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights		three-year
Performance Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			120,000
Performance Share Units | 2021 Incentive Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights		three years

Stock-based Compensation Plan_3

Stock-based Compensation Plans - Summary of Transactions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized in:	$ 59	$ 40	$ 41
Income tax benefits	12	8	9
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized in:	11	17	16
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized in:	36	19	21
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized in:	$ 12	$ 4	$ 4

Stock-based Compensation Plan_4

Stock-based Compensation Plans - Stock Option Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Expected dividend yield	3.22%
Risk-free interest rate	0.92%
Expected volatility	45.80%
Expected term (years)	5 years 10 months 20 days

Stock-based Compensation Plan_5

Stock-based Compensation Plans - Summary of Transactions (Details)	7 Months Ended
	Dec. 31, 2021$ / sharesshares
Stock Options
Outstanding at June 2, 2021 (in shares) | shares	4,097,000
Grants (in shares) | shares	379,000
Exercised (in shares) | shares	0
Forfeited or expired (in shares) | shares	(82,000)
Outstanding at September 30, 2021 (in shares) | shares	4,394,000
Stock Options Weighted Average Exercise Price
Options outstanding, Weighted average exercise price per share - June 2, 2021 (in usd per share)	$ 34.30
Options Granted, Weighted average exercise price per share (in usd per share)	35.38
Options Vested/Exercised, Weighted average exercise price per share (in usd per share)	0
Options Forfeited/Cancelled, Weighted average exercise price per share (in usd per share)	36.52
Options outstanding, Weighted average exercise price per share - September 30, 2021 (in usd per share)	34.35
Stock Options Weighted Average Grant Date Fair Value
Options outstanding, Weighted average grant date fair value price per share - June 2, 2021 (in usd per share)	8.55
Granted, Weighted average grant date fair value price per share (in usd per share)	11.20
Vested/Exercised, Weighted average grant date fair value price per share (in usd per share)	0
Forfeited/Cancelled, Weighted average grant date fair value price per share (in usd per share)	9.05
Options outstanding, Weighted average grant date fair value price per share - September 30, 2021 (in usd per share)	$ 8.63
Restricted Share Units
Outstanding Share Awards
Outstanding as of June 2, 2021 (in shares) | shares	3,311,000
Granted (in shares) | shares	88,000
Vested/ Exercised (in shares) | shares	(52,000)
Forfeited/Cancelled (in shares) | shares	(67,000)
Outstanding at September 30, 2021 (in shares) | shares	3,280,000
Weighted Average Grant Date Fair Value
Outstanding, Weighted average grant date fair value at June 2, 2021 (in USD per share)	$ 36.77
Granted, Weighted average grant date fair value (in USD per share)	34.72
Vested/Exercised, Weighted average grant date fair value (in USD per share)	38.46
Forfeited/Cancelled, Weighted average grant date fair value (in USD per share)	36.55
Outstanding, Weighted average grant date fair value at September 30, 2021 (in USD per share)	$ 36.69
Performance Share Units
Outstanding Share Awards
Outstanding as of June 2, 2021 (in shares) | shares	0
Granted (in shares) | shares	120,000
Vested/ Exercised (in shares) | shares	0
Forfeited/Cancelled (in shares) | shares	0
Outstanding at September 30, 2021 (in shares) | shares	120,000
Weighted Average Grant Date Fair Value
Outstanding, Weighted average grant date fair value at June 2, 2021 (in USD per share)	$ 0
Granted, Weighted average grant date fair value (in USD per share)	51.63
Vested/Exercised, Weighted average grant date fair value (in USD per share)	0
Forfeited/Cancelled, Weighted average grant date fair value (in USD per share)	0
Outstanding, Weighted average grant date fair value at September 30, 2021 (in USD per share)	$ 51.63

Stock-based Compensation Plan_6

Stock-based Compensation Plans - Equity Awards Outstanding (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Equity Awards Vested and Expected to Vest
Stock Options, Awards (in shares) | shares	4,134,000
Stock Options, Average Price (in usd per share) | $ / shares	$ 34.35
Stock Options, Aggregate Intrinsic Value | $	$ 2
Stock Options, Remaining Term (in years)	8 years 7 days
Equity Awards That are Exercisable
Stock Options, Awards (in shares) | shares	1,454,000
Stock Options, Average Price (in usd per share) | $ / shares	$ 30.66
Stock Options, Aggregate Intrinsic Value | $	$ 2
Stock Options, Remaining Term	5 years 7 months 24 days
Restricted Share Units
Equity Awards Vested and Expected to Vest
Restricted Stock, Awards (in shares) | shares	3,051,000
Restricted Stock, Average Price (in usd per share) | $ / shares	$ 0
Restricted Stock, Aggregate Intrinsic Value | $	$ 100
Restricted Stock, Remaining Term	1 year 11 months 26 days
Equity Awards That are Exercisable
Restricted Stock, Awards (in shares) | shares	0
Restricted Stock, Average Price (in usd per share) | $ / shares	$ 0
Restricted Stock, Aggregate Intrinsic Value | $	$ 0
Performance Share Units
Equity Awards Vested and Expected to Vest
Restricted Stock, Awards (in shares) | shares	102,000
Restricted Stock, Average Price (in usd per share) | $ / shares	$ 0
Restricted Stock, Aggregate Intrinsic Value | $	$ 4
Restricted Stock, Remaining Term	2 years 7 months 17 days
Equity Awards That are Exercisable
Restricted Stock, Awards (in shares) | shares	0
Restricted Stock, Average Price (in usd per share) | $ / shares	$ 0
Restricted Stock, Aggregate Intrinsic Value | $	$ 0

Pension and Other Postretirem_3

Pension and Other Postretirement Benefit Plans - Narrative (Details) - USD ($) $ in Millions	Jun. 02, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Total benefit plan expense		$ 29	$ 55	$ 29
Increase for "grow-in" provision	$ 50	$ 46
Estimated average service period		8 years
Expected contributions for 2022		$ 9
2022		6
2023		8
2024		7
2025		6
2026		7
2027-2031		41
Employer contributions		23	$ 18	$ 18
Other Assets
Defined Benefit Plan Disclosure [Line Items]
Increase for "grow-in" provision		40
Other Current Assets
Defined Benefit Plan Disclosure [Line Items]
Increase for "grow-in" provision		$ 6

Pension and Other Postretirem_4

Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Service cost	$ 17	$ 4	$ 3
Interest cost	2	1	1
Expected return on plan assets	(3)	(1)	(1)
Net loss amortization	2	0	0
Net periodic benefit cost	$ 18	$ 4	$ 3

Pension and Other Postretirem_5

Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets January 1	$ 40	$ 28
Actual return on plan assets	6	0
Company contributions	19	4
Effects of exchange rate changes	(6)	3
Benefits paid	2	(1)
Other	0	7
Net transfer of plan assets from Merck affiliates	56	(1)
Fair value of plan assets December 31	117	40	$ 28
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation January 1	76	54
Service cost	17	4	3
Interest cost	2	1	1
Actuarial losses	(17)	4
Benefits paid	2	(1)
Effects of exchange rate changes	(10)	6
Other	0	6
Net transfer of benefit obligations from Merck affiliates	119	2
Benefit obligation December 31	189	76	$ 54
Funded status December 31	(72)	(36)
Recognized as:
Other assets	1	0
Accrued and other current liabilities	(1)	0
Other Noncurrent liabilities	$ (72)	$ (36)

Pension and Other Postretirem_6

Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Pension plans with a projected benefit obligation in excess of plan assets, Projected benefit obligation	$ 176	$ 76
Pension plans with a projected benefit obligation in excess of plan assets, Fair value of plan assets	104	38
Pension plans with an accumulated benefit obligation in excess of plan assets, Accumulated benefit obligation	154	54
Pension plans with an accumulated benefit obligation in excess of plan assets, Fair value of plan assets	$ 97	$ 38

Pension and Other Postretirem_7

Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	$ 117	$ 40	$ 28
Pension Plan
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	117	40
Pension Plan | Cash and cash equivalents
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	3	0
Pension Plan | Developed markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	31	0
Pension Plan | Government and agency obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	22	0
Pension Plan | Emerging markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	5	0
Pension Plan | Other
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	4	0
Pension Plan | Developed markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	1	0
Pension Plan | Government and agency obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	3	5
Pension Plan | Corporate Obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	2	0
Pension Plan | Insurance contracts
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	33	34
Pension Plan | Other
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	13	1
Pension Plan | Level 1
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	73	0
Pension Plan | Level 1 | Cash and cash equivalents
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	3	0
Pension Plan | Level 1 | Developed markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	28	0
Pension Plan | Level 1 | Government and agency obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	21	0
Pension Plan | Level 1 | Emerging markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	5	0
Pension Plan | Level 1 | Other
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	3	0
Pension Plan | Level 1 | Developed markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	1	0
Pension Plan | Level 1 | Government and agency obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 1 | Corporate Obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 1 | Insurance contracts
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 1 | Other
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	12	0
Pension Plan | Level 2
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	44	40
Pension Plan | Level 2 | Cash and cash equivalents
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 2 | Developed markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	3	0
Pension Plan | Level 2 | Government and agency obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	1	0
Pension Plan | Level 2 | Emerging markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 2 | Other
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	1	0
Pension Plan | Level 2 | Developed markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 2 | Government and agency obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	3	5
Pension Plan | Level 2 | Corporate Obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	2	0
Pension Plan | Level 2 | Insurance contracts
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	33	34
Pension Plan | Level 2 | Other
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	1	1
Pension Plan | Level 3
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 3 | Cash and cash equivalents
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 3 | Developed markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 3 | Government and agency obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 3 | Emerging markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 3 | Other
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 3 | Developed markets equities
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 3 | Government and agency obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 3 | Corporate Obligations
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 3 | Insurance contracts
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	0	0
Pension Plan | Level 3 | Other
Defined Benefit Plan, Plan Assets, Category [Line Items]
Plan assets at fair value	$ 0	$ 0

Pension and Other Postretirem_8

Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Net gain (loss) arising during the period	$ 4	$ 6	$ (5)
Net loss amortization included in benefit cost	$ 2	$ 0	$ 0

Pension and Other Postretirem_9

Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net periodic benefit cost
Discount rate	1.48%	3.91%	4.14%
Expected rate of return on plan assets	4.50%	2.62%	3.08%
Salary growth rate	3.18%	3.63%	3.36%
Benefit obligation
Discount rate	1.49%	1.52%	1.63%
Salary growth rate	2.75%	3.63%	3.33%

Other (Income) Expense, Net (De

Other (Income) Expense, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Income and Expenses [Abstract]
Exchange (gains) losses	$ 4	$ 44	$ 73
Interest expense	258	0	0
Other, net	17	(9)	(7)
Other (income) expense, net	$ 279	$ 35	$ 66

Taxes on Income - Narrative (De

Taxes on Income - Narrative (Details) - USD ($) $ in Millions	Jun. 02, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Examination [Line Items]
Transition tax liability		$ 0	$ 1,500
Transition tax liability, current			161
Transition tax liability, noncurrent			$ 1,300
Effective income tax rate		11.70%	18.00%	10.60%
Deferred tax assets on NOL carryforwards		$ 103	$ 70
Decrease in amount of valuation allowance		42
Income taxes paid		131
Intra-entity transfers of inventory		377	421
Tax benefits recognized related to settlement		15	19	$ 140
Unrecognized tax benefits		78	219	213	$ 619
Unrecognized tax benefits that would impact tax rate		78
Decrease in unrecognized tax benefits is reasonably possible		11
Interest and penalties with uncertain tax positions			11	(48)
Accrued interest and penalties		39	68
Tax year 2015-2016
Income Tax Examination [Line Items]
Tax benefits recognized related to settlement		29
Merck and Co., Inc.
Income Tax Examination [Line Items]
Income taxes paid		18	$ 416	1,100
Foreign Tax Authority
Income Tax Examination [Line Items]
Step-up in tax basis		75
Valuation allowances		35
Uncertain tax positions for jurisdictions outside the U.S.	$ 79.3
Decrease resulting from spin-off		$ 79.3
Domestic Tax Authority | Internal Revenue Service (IRS)
Income Tax Examination [Line Items]
Income taxes paid				142
Tax benefits recognized related to settlement				$ 258

Taxes on Income - Income Before

Taxes on Income - Income Before Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Domestic	$ (96)	$ 532	$ 564
Foreign	1,625	2,220	3,132
Income From Continuing Operations Before Income Taxes	$ 1,529	$ 2,752	$ 3,696

Taxes on Income - Taxes on Inco

Taxes on Income - Taxes on Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current provision
Federal	$ 41	$ 91	$ (126)
Foreign	435	435	549
State	(10)	2	(45)
Current Income Tax Expense (Benefit)	466	528	378
Deferred provision
Federal	(64)	11	3
Foreign	(220)	(44)	(10)
State	(4)	1	19
Deferred income taxes	(288)	(32)	12
Taxes on Income	$ 178	$ 496	$ 390

Taxes on Income - Reconciliatio

Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Amount
U.S. statutory rate applied to income before taxes	$ 321	$ 578	$ 776
Differential arising from:
Foreign earnings	(43)	(93)	(143)
Tax settlements	(32)	0	(264)
Amortization of intangible assets	(75)	12	22
State taxes	(3)	0	5
Global Intangible Low-Taxed Income	17	0
Other	(7)	(1)	(6)
Taxes on Income	$ 178	$ 496	$ 390
Tax Rate
U.S. statutory rate applied to income before taxes	21.00%	21.00%	21.00%
Differential arising from:
Foreign earnings	(2.80%)	(3.40%)	(3.90%)
Tax settlements	(2.10%)	0.00%	(7.10%)
Amortization of intangible assets	(4.90%)	0.40%	0.60%
State taxes	(0.20%)	0.00%	0.10%
Global Intangible Low-Taxed Income	1.10%
Other	(0.40%)	0.00%	(0.10%)
Total, Tax Rate	11.70%	18.00%	10.60%

Taxes on Income - Deferred Inco

Taxes on Income - Deferred Income Taxes (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets
Product intangibles and licenses	$ 105	$ 24
Inventory related	15	0
Reserves and allowances	40	39
Accrued expenses	23	0
Accelerated depreciation	0	0
Right of use asset	51	0
Interest expense limitation carryforward	23	0
Compensation related	23	0
Unrecognized tax benefits	0	18
Hedging	0	0
Net operating losses and other tax credit carryforwards	103	70
Other	24	36
Subtotal	407	187
Valuation allowance	(35)	(69)
Total deferred taxes	372	118
Net deferred income taxes	268	22
Liabilities
Product intangibles and licenses	0	0
Inventory related	0	18
Accelerated depreciation	15	0
Lease liability	51	0
Unremitted foreign earnings	2	78
Hedging	36	0
Other	0	0
Subtotal	104	96
Other Assets
Assets
Total deferred taxes	272	150
Deferred Income Taxes
Liabilities
Subtotal	$ 4	$ 128

Taxes on Income - Unrecognized

Taxes on Income - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance January 1	$ 219	$ 213	$ 619
Additions related to current year tax positions	23	15	12
Additions related to prior year tax positions	18	23	4
Reductions for tax positions of prior years	(49)	(3)	(274)
Spin-off related adjustments	(108)	0	0
Settlements	(15)	(19)	(140)
Lapse of statute of limitations	(10)	(10)	(8)
Balance December 31	78	$ 219	$ 213
Merck and Co., Inc.
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Reductions for tax positions of prior years	$ (108)

Other Comprehensive Income (L_3

Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ 5,486	$ 7,035	$ 6,348
Other comprehensive income (loss), pretax	111	(202)	(14)
Tax	(13)	29	8
Other comprehensive income (loss), net of taxes	98	(173)	(6)
Net transfer of benefit plans to Merck affiliates	11	465
Ending balance	(1,508)	5,486	7,035
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(622)	(914)	(908)
Ending balance	(513)	(622)	(914)
Employee Benefit Plans
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(32)	(354)	(294)
Other comprehensive income (loss), pretax	21	(172)	(68)
Tax	(13)	29	8
Other comprehensive income (loss), net of taxes	8	(143)	(60)
Net transfer of benefit plans to Merck affiliates	11	465
Ending balance	(13)	(32)	(354)
Cumulative Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(590)	(560)	(614)
Other comprehensive income (loss), pretax	90	(30)	54
Other comprehensive income (loss), net of taxes	90	(30)	54
Ending balance	$ (500)	$ (590)	$ (560)

Product and Geographic Inform_3

Product and Geographic Information - Narrative (Details)	12 Months Ended
	Dec. 31, 2021segment
Segment Reporting [Abstract]
Number of operating segments	1
Long-Lived Assets, Geographic Area | Geographic Concentration Risk | Europe and Canada
Concentration Risk [Line Items]
Concentration risk	80.00%
Long-Lived Assets, Geographic Area | Geographic Concentration Risk | U.S.
Concentration Risk [Line Items]
Concentration risk	10.00%

Product and Geographic Inform_4

Product and Geographic Information - Sales of Company's Products (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from External Customer [Line Items]
Revenues	$ 6,304	$ 6,532	$ 7,777
Nexplanon/Implanon NXT
Revenue from External Customer [Line Items]
Revenues	769	680	787
Follistim AQ
Revenue from External Customer [Line Items]
Revenues	237	193	241
NuvaRing
Revenue from External Customer [Line Items]
Revenues	191	236	879
ganirelix acetate injection
Revenue from External Customer [Line Items]
Revenues	111	81	112
Cerazette
Revenue from External Customer [Line Items]
Revenues	70	67	71
Other Womens Health
Revenue from External Customer [Line Items]
Revenues	234	298	173
Renflexis
Revenue from External Customer [Line Items]
Revenues	186	135	96
Ontruzant
Revenue from External Customer [Line Items]
Revenues	126	115	83
Brenzys
Revenue from External Customer [Line Items]
Revenues	63	74	72
Other Biosimilars
Revenue from External Customer [Line Items]
Revenues	49	6	0
Zetia
Revenue from External Customer [Line Items]
Revenues	378	482	590
Vytorin
Revenue from External Customer [Line Items]
Revenues	164	182	285
Atozet
Revenue from External Customer [Line Items]
Revenues	458	453	391
Rosuzet
Revenue from External Customer [Line Items]
Revenues	68	130	120
Cozaar/Hyzaar
Revenue from External Customer [Line Items]
Revenues	357	386	442
Zocor
Revenue from External Customer [Line Items]
Revenues	65	77	112
Other Cardiovascular
Revenue from External Customer [Line Items]
Revenues	126	162	134
Singulair
Revenue from External Customer [Line Items]
Revenues	413	462	698
Nasonex
Revenue from External Customer [Line Items]
Revenues	206	218	293
Dulera
Revenue from External Customer [Line Items]
Revenues	190	222	217
Clarinex
Revenue from External Customer [Line Items]
Revenues	111	130	142
Asmanex
Revenue from External Customer [Line Items]
Revenues	63	83	94
Other Respiratory
Revenue from External Customer [Line Items]
Revenues	26	35	25
Arcoxia
Revenue from External Customer [Line Items]
Revenues	244	258	288
Fosamax
Revenue from External Customer [Line Items]
Revenues	175	180	197
Diprospan
Revenue from External Customer [Line Items]
Revenues	125	118	102
Diprosone
Revenue from External Customer [Line Items]
Revenues	87	83	84
Other Non-Opiod Pain, Bone and Dermatology
Revenue from External Customer [Line Items]
Revenues	199	195	214
Proscar
Revenue from External Customer [Line Items]
Revenues	117	176	203
Propecia
Revenue from External Customer [Line Items]
Revenues	136	129	131
Sinemet
Revenue from External Customer [Line Items]
Revenues	71	77	79
Remeron
Revenue from External Customer [Line Items]
Revenues	66	64	82
Other
Revenue from External Customer [Line Items]
Revenues	223	238	238
Other
Revenue from External Customer [Line Items]
Revenues	200	107	102
U.S.
Revenue from External Customer [Line Items]
Revenues	1,383	1,408	2,021
U.S. | Nexplanon/Implanon NXT
Revenue from External Customer [Line Items]
Revenues	532	488	568
U.S. | Follistim AQ
Revenue from External Customer [Line Items]
Revenues	110	84	103
U.S. | NuvaRing
Revenue from External Customer [Line Items]
Revenues	85	111	744
U.S. | ganirelix acetate injection
Revenue from External Customer [Line Items]
Revenues	22	11	25
U.S. | Cerazette
Revenue from External Customer [Line Items]
Revenues	0	0	0
U.S. | Other Womens Health
Revenue from External Customer [Line Items]
Revenues	96	165	18
U.S. | Renflexis
Revenue from External Customer [Line Items]
Revenues	164	123	95
U.S. | Ontruzant
Revenue from External Customer [Line Items]
Revenues	34	3	0
U.S. | Brenzys
Revenue from External Customer [Line Items]
Revenues	0	0	0
U.S. | Other Biosimilars
Revenue from External Customer [Line Items]
Revenues	0	0	0
U.S. | Zetia
Revenue from External Customer [Line Items]
Revenues	10	(1)	14
U.S. | Vytorin
Revenue from External Customer [Line Items]
Revenues	11	12	16
U.S. | Atozet
Revenue from External Customer [Line Items]
Revenues	0	0	0
U.S. | Rosuzet
Revenue from External Customer [Line Items]
Revenues	0	0	0
U.S. | Cozaar/Hyzaar
Revenue from External Customer [Line Items]
Revenues	12	21	25
U.S. | Zocor
Revenue from External Customer [Line Items]
Revenues	4	3	6
U.S. | Other Cardiovascular
Revenue from External Customer [Line Items]
Revenues	0	0	0
U.S. | Singulair
Revenue from External Customer [Line Items]
Revenues	15	18	30
U.S. | Nasonex
Revenue from External Customer [Line Items]
Revenues	4	12	9
U.S. | Dulera
Revenue from External Customer [Line Items]
Revenues	154	188	189
U.S. | Clarinex
Revenue from External Customer [Line Items]
Revenues	6	7	8
U.S. | Asmanex
Revenue from External Customer [Line Items]
Revenues	57	76	84
U.S. | Other Respiratory
Revenue from External Customer [Line Items]
Revenues	0	3	1
U.S. | Arcoxia
Revenue from External Customer [Line Items]
Revenues	0	0	0
U.S. | Fosamax
Revenue from External Customer [Line Items]
Revenues	4	4	9
U.S. | Diprospan
Revenue from External Customer [Line Items]
Revenues	0	0	0
U.S. | Diprosone
Revenue from External Customer [Line Items]
Revenues	1	1	1
U.S. | Other Non-Opiod Pain, Bone and Dermatology
Revenue from External Customer [Line Items]
Revenues	15	9	14
U.S. | Proscar
Revenue from External Customer [Line Items]
Revenues	1	2	2
U.S. | Propecia
Revenue from External Customer [Line Items]
Revenues	9	10	11
U.S. | Sinemet
Revenue from External Customer [Line Items]
Revenues	0	(1)	1
U.S. | Remeron
Revenue from External Customer [Line Items]
Revenues	3	2	3
U.S. | Other
Revenue from External Customer [Line Items]
Revenues	37	53	62
U.S. | Other
Revenue from External Customer [Line Items]
Revenues	(3)	4	(17)
International
Revenue from External Customer [Line Items]
Revenues	4,921	5,124	5,756
International | Nexplanon/Implanon NXT
Revenue from External Customer [Line Items]
Revenues	237	192	219
International | Follistim AQ
Revenue from External Customer [Line Items]
Revenues	127	108	138
International | NuvaRing
Revenue from External Customer [Line Items]
Revenues	106	126	134
International | ganirelix acetate injection
Revenue from External Customer [Line Items]
Revenues	88	69	86
International | Cerazette
Revenue from External Customer [Line Items]
Revenues	70	67	71
International | Other Womens Health
Revenue from External Customer [Line Items]
Revenues	139	133	156
International | Renflexis
Revenue from External Customer [Line Items]
Revenues	21	12	1
International | Ontruzant
Revenue from External Customer [Line Items]
Revenues	92	113	83
International | Brenzys
Revenue from External Customer [Line Items]
Revenues	63	74	72
International | Other Biosimilars
Revenue from External Customer [Line Items]
Revenues	49	6	0
International | Zetia
Revenue from External Customer [Line Items]
Revenues	368	483	575
International | Vytorin
Revenue from External Customer [Line Items]
Revenues	153	170	268
International | Atozet
Revenue from External Customer [Line Items]
Revenues	458	453	391
International | Rosuzet
Revenue from External Customer [Line Items]
Revenues	68	130	120
International | Cozaar/Hyzaar
Revenue from External Customer [Line Items]
Revenues	345	365	417
International | Zocor
Revenue from External Customer [Line Items]
Revenues	61	75	107
International | Other Cardiovascular
Revenue from External Customer [Line Items]
Revenues	126	162	134
International | Singulair
Revenue from External Customer [Line Items]
Revenues	398	444	669
International | Nasonex
Revenue from External Customer [Line Items]
Revenues	201	206	284
International | Dulera
Revenue from External Customer [Line Items]
Revenues	36	34	29
International | Clarinex
Revenue from External Customer [Line Items]
Revenues	106	123	133
International | Asmanex
Revenue from External Customer [Line Items]
Revenues	7	8	9
International | Other Respiratory
Revenue from External Customer [Line Items]
Revenues	26	32	25
International | Arcoxia
Revenue from External Customer [Line Items]
Revenues	244	258	288
International | Fosamax
Revenue from External Customer [Line Items]
Revenues	172	176	188
International | Diprospan
Revenue from External Customer [Line Items]
Revenues	125	118	102
International | Diprosone
Revenue from External Customer [Line Items]
Revenues	86	82	83
International | Other Non-Opiod Pain, Bone and Dermatology
Revenue from External Customer [Line Items]
Revenues	183	186	199
International | Proscar
Revenue from External Customer [Line Items]
Revenues	116	174	202
International | Propecia
Revenue from External Customer [Line Items]
Revenues	127	119	120
International | Sinemet
Revenue from External Customer [Line Items]
Revenues	71	78	78
International | Remeron
Revenue from External Customer [Line Items]
Revenues	62	61	79
International | Other
Revenue from External Customer [Line Items]
Revenues	185	185	176
International | Other
Revenue from External Customer [Line Items]
Revenues	$ 205	$ 102	$ 120

Product and Geographic Inform_5

Product and Geographic Information - Revenues by Geographic Area (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from External Customer [Line Items]
Revenues	$ 6,304	$ 6,532	$ 7,777
Europe and Canada
Revenue from External Customer [Line Items]
Revenues	1,741	1,726	1,893
United States
Revenue from External Customer [Line Items]
Revenues	1,383	1,408	2,021
Asia Pacific and Japan
Revenue from External Customer [Line Items]
Revenues	1,173	1,535	1,789
China
Revenue from External Customer [Line Items]
Revenues	933	873	1,027
Latin America, Middle East, Russia and Africa
Revenue from External Customer [Line Items]
Revenues	841	857	923
Other
Revenue from External Customer [Line Items]
Revenues	$ 233	$ 133	$ 124

Third Party Arrangements and _3

Third Party Arrangements and Related Party Disclosures - Allocations Included in Statement of Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Cost of sales	$ 2,382	$ 2,119	$ 2,274
Selling, general and administrative	1,668	1,356	1,443
Research and development	443	210	220
Costs, Expenses And Other	4,775	3,780	4,081
Related Party | Merck and Co., Inc. | Transition Services Agreement
Related Party Transaction [Line Items]
Cost of sales	69	452	520
Selling, general and administrative	134	658	725
Research and development	35	152	190
Costs, Expenses And Other	$ 238	$ 1,262	$ 1,435

Third Party Arrangements and _4

Third Party Arrangements and Related Party Disclosures - Transactions with Merck Affiliates (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Discontinued Operations
Related Party Transaction [Line Items]
Supply sales to Merck affiliates	$ 12	$ 542	$ 501
Purchases from Merck affiliates	53	382	1,100
Other Merck Affiliates | Continuing Operations
Related Party Transaction [Line Items]
Supply sales to Merck affiliates	143	57	0
Purchases from Merck affiliates	65	657	0
Other Merck Affiliates | Continuing Operations | Cost reimbursements and fees from Merck affiliates
Related Party Transaction [Line Items]
Amounts of transaction	1	0	0
Other Merck Affiliates | Discontinued Operations
Related Party Transaction [Line Items]
Supply sales to Merck affiliates	12	542	501
Purchases from Merck affiliates	53	382	1,087
Amounts of transaction		2	3
Other Merck Affiliates | Discontinued Operations | Cost reimbursements and fees from Merck affiliates
Related Party Transaction [Line Items]
Amounts of transaction	0	$ 22	$ 19
Other Merck Affiliates | Discontinued Operations | Interest expense, net on loans and advances with Merck affiliates
Related Party Transaction [Line Items]
Amounts of transaction	$ 0

Third Party Arrangements and _5

Third Party Arrangements and Related Party Disclosures - Balances with Merck Affiliates (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Due to related party	$ 0	$ 1,339
Related Party | Continuing Operations | Merck and Co., Inc.
Related Party Transaction [Line Items]
Short term borrowings, net		1,512
Trade payables (receivables), net		(173)
Due to related party		1,339
Related Party | Discontinued Operations | Merck and Co., Inc.
Related Party Transaction [Line Items]
Short term loans receivables, net		247
Short term notes payable, net		(25)
Trade payables, net		(33)
Due from related party		$ 189

Third Party Arrangements and _6

Third Party Arrangements and Related Party Disclosures - Net Transfers to Parent (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Cash pooling and general financing activities	$ 168	$ 5,216	$ 5,310
Cost allocations, excluding non-cash stock-based compensation	(209)	(1,222)	(1,394)
Taxes deemed settled with Merck	(259)	(409)	(1,039)
Allocated derivative and hedging (losses) gains	(88)	(51)	55
Net transfers (from) to Merck & Co., Inc. as reflected in the Consolidated Statement of Cash Flows for Continuing Operations(2)	(388)	3,534	2,932
Net transfers to (from) Merck included in Net Cash Provided by (Used in) Discontinued Operations	597	(194)	(355)
Total net transfers to Merck as included in the Consolidated Statement of Cash Flows	209	3,340	2,577
Stock-based compensation expense (includes $3 and $7 of discontinued operations for 2021 and 2020, respectively)	(32)	(54)	(52)
Net assets (distributed to) contributed by Merck affiliates	(778)	250	0
Recognition of amounts in Accumulated other comprehensive loss related to employee benefit plan transfers to Merck affiliates	13	465	0
Net transfers (from) to Merck & Co., Inc. as reflected in the Consolidated Statement of Equity		3,536	2,525
Adjustment to net transfers reflected in Cash Flows from Continuing Operations	52
Merck and Co., Inc.
Related Party Transaction [Line Items]
Net transfers (from) to Merck & Co., Inc. as reflected in the Consolidated Statement of Equity	(588)	4,001	$ 2,525
Discontinued Operations
Related Party Transaction [Line Items]
Stock-based compensation expense (includes $3 and $7 of discontinued operations for 2021 and 2020, respectively)	$ 3	$ 7

Third Party Arrangements and _7

Third Party Arrangements and Related Party Disclosures - Narrative (Details) - USD ($) $ in Millions	Jun. 02, 2021	Apr. 30, 2021	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
TSA termination period	25 months
Breach of covenant period	2 years
Accounts receivable				$ 403	$ 403
Accounts payable				928	928
Dividend payments		$ 9,000	$ 9,000
Cash and cash equivalents				737	737	$ 12
Foreign Tax Authority
Related Party Transaction [Line Items]
Uncertain tax positions for jurisdictions outside the U.S.	$ 79.3
Transfers Between Organon Entities, the Transferring Entities and Merck Affiliates
Related Party Transaction [Line Items]
Accounts receivables, net					751
Inventories					265
Transition tax liabilities					1,400
Certain liabilities					210
Contribution of Assets
Related Party Transaction [Line Items]
Contribution of assets					59
Contribution of liabilities					35
Related Party
Related Party Transaction [Line Items]
Related party sales					90
Cost of sales					$ 85
Reserve for inventory purchases				$ 400

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - Discontinued Operations - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Related party sales	$ 12	$ 542	$ 501
Costs for inventory purchases	$ 53	$ 382	$ 1,100

Discontinued Operations - Compo

Discontinued Operations - Components of Income (Loss) from Discontinued Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Costs, Expenses and Other
Loss from discontinued operations, net of taxes	$ 0	$ (96)	$ (88)
Discontinued Operations, Held-for-sale or Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales	93	1,564	1,753
Costs, Expenses and Other
Cost of Sales	65	1,228	1,347
Selling, general and administrative	15	310	479
Research and development	4	94	112
Restructuring costs	0	10	23
Other (income) expense, net	4	(6)	(67)
Income (loss) from discontinued operations before taxes	5	(72)	(141)
Taxes on income	5	24	(53)
Loss from discontinued operations, net of taxes	$ 0	$ (96)	$ (88)

Discontinued Operations - Com_2

Discontinued Operations - Components of Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 0	$ 58	$ 319	$ 244
Total current assets of discontinued operations	0	674
Noncurrent assets of discontinued operations	0	91
Liabilities
Total current liabilities of discontinued operations	0	128
Total Noncurrent Liabilities of Discontinued Operations	$ 0	83
Discontinued Operations, Held-for-sale or Disposed of by Sale
Assets
Cash and cash equivalents		58
Accounts receivable		322
Inventories		58
Due from related party		189
Other current assets		47
Total current assets of discontinued operations		674
Property, Plant and Equipment, net		14
Other Noncurrent Assets		77
Noncurrent assets of discontinued operations		91
Total Assets of Discontinued Operations		765
Liabilities
Trade accounts payable		35
Accrued and other current liabilities		93
Total current liabilities of discontinued operations		128
Deferred Income Taxes		0
Other Noncurrent Liabilities		83
Total Noncurrent Liabilities of Discontinued Operations		83
Total Liabilities of Discontinued Operations		$ 211

Earnings per Share - Calculatio

Earnings per Share - Calculation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Net income from continuing operations	$ 1,351	$ 2,256	$ 3,306
Income from discontinued operations	0	(96)	(88)
Net Income	$ 1,351	$ 2,160	$ 3,218
Basic weighted average number of shares outstanding	253,537,941	253,516,000	253,516,000
Stock awards and equity units (share equivalent)	655,000	0	0
Diluted weighted average common shares outstanding	254,192,700	253,516,000	253,516,000
Earnings (Loss) per Share Attributable to Organon & Co. Stockholders - Basic:
Continuing operations (in dollars per share)	$ 5.33	$ 8.90	$ 13.04
Loss from discontinued operations (in dollars per share)	0	(0.38)	(0.35)
Net Earnings per Share Attributable to Organon & Co. Stockholders - Basic (in dollars per share)	5.33	8.52	12.69
Earnings (Loss) per Share Attributable to Organon & Co. Stockholders - Diluted:
Continuing operations (in dollars per share)	5.31	8.90	13.04
Loss from discontinued operations (in dollars per share)	0	(0.38)	(0.35)
Net Earnings per Share Attributable to Organon & Co. Stockholders - Diluted (in dollars per share)	$ 5.31	$ 8.52	$ 12.69

Earnings per Share - Narrative

Earnings per Share - Narrative (Details) - $ / shares shares in Millions	Dec. 16, 2021	Sep. 13, 2021	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cash dividends paid (in dollar per share)	$ 0.28	$ 0.28	$ 0.56
Share-based compensation plans
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			4.9